SCREENING METHOD FOR CANDIDATE DRUGS

Abstract: The present invention relates to a method for screening molecules and a method to detect protein-protein interactions.

Description: Screening method for candidate drugs Description The present invention relates to screening methods for candidate drugs effective in treating or detecting MIF (macrophage migration inhibitory factor) related diseases, and means used therein. In response to antigenic or mitogenic stimulation, lymphocytes secret protein mediators called lymphokines that play an important role in immunoregu- lation, inflammation, stress response, and effector mechanisms of cellular immunity. The first reported lymphokine activity was observed in culture supernatants of antigenically sensitised and activated guinea pig lymphocytes. This activity was named migration inhibitory factor (MIF) for its ability to prevent the migration of guinea pig macrophages out of capillary tubes in vitro. MIF has also been identified as a secretable product of macrophages, anterior pituitary cells and endothe- lial cells activating both macrophages and T- lymphocytes and certain other cell types. The detection of MIF activity is correlated with a variety of inflammatory responses including delayed hypersensitivity and cellular immunity, allograft rejection, rheumatoid polyarthritic synovialis, and autoimmune diseases. In addition, MIF has enzymatic activity, showing both tautomerase and thiol- protein oxidoreductase activity. MIF has various proinflammatory properties. In this function, MIF was demonstrated to be a mediator of several inflammatory diseases including Gram-negative and Gram-positive septic shock, adult respiratory distress syndrome, and its pro-inflammatory properties are due in part to its capacity to induce the release of other proinflammatory cytokines, such as interleukin-1, tumour necrosis factor and by the counterregulation of glucocorticoid action. MIF also plays a role in the regulation of cellular redox homeostasis. Despite functional similarities with other cytokines, MIF exhibits a number of characteristic features. For example, MIF expression is not restricted to cells of the immune and endocrine systems and MIF protein is found preformed in most MIF-expressing cells. Although of tremendous importance for the development of diagnostic and therapeutic tools for MIF- related diseases, the molecular targets of MIF action have not been identified; MIF could have direct intracellular functions based on interactions with intracellular proteins. Molecules - so-called drugs - which disrupt, prevent, enhance or modulate interaction of MIF with other proteins can influence the key role of MIF in cell cycle control, im- muno-modulation, redox-effects and regulatory pathways . In principle, the interaction of MIF with other proteins can be tested with a two-hybrid system. The yeast two-hybrid system has been used to detect the association of pairs of proteins (see, e.g., Fields et al . , US Pat. No. 5,283,173). This method involves in vivo reconstitution of two separable domains of a transcription factor. The DNA binding domain of the transcription factor is required for recognition of a chosen promoter. The activation domain is required for contacting other components of the cell's transcriptional machinery. In this system, the transcription factor is reconstituted through the use of hybrid proteins. One hybrid is composed of the activation domain and a first protein of interest . The second hybrid is composed of the binding domain and a second protein of interest . In cases where the first and second proteins of interest interact with each other, the activation domain and binding domain are brought into close physical proximity, thereby reconstituting the transcription factor. Association of the proteins can be measured by assaying the ability of the reconstituted transcription factor to activate transcription of a reporter gene. Methods and compositions for drug screening are known (US patent 5,569,588). A method for modelling the transcriptional responsiveness of an organism to a candidate drug involves for instance (a) detecting reporter gene product signals from each of a plurality of different, separately isolated cells of a target organism, wherein each cell contains a recombinant construct comprising a reporter gene operatively linked to a different endogenous transcriptional regulatory element of the target organism such that the transcriptional regulatory element regulates the expression of the reporter gene, and the sum of the cells comprises an ensemble of the transcriptional regulatory elements of the organism sufficient to model the transcriptional responsiveness of the organism to a drug; (b) contacting each cell with a candidate drug; (c) detecting reporter gene product signals from each cell; (d) comparing reporter gene product signals from each cell before and after contacting the cell with the candidate drug to obtain a drug response profile which provides a model of the transcriptional responsiveness of the organism to the candidate drug. Thus, it is considered particularly important to develop and provide methods and means that allow (i) the detection of the interaction of MIF with an intracellular target molecule, for instance a protein and (ii) the identification of molecules which modify this interaction of MIF with the intracellular target molecule. Thus, the technical problem underlying the present invention is to provide means and methods for screening drugs effective in diagnosing and treating MIF-related diseases. The present invention solves this problem by providing a method for screening candidate drugs effective in diagnosing and treating MIF-related diseases by testing whether the candidate drug disrupts interaction, in particular, binding between MIF and Jabl, and/or interferes with a MIF/Jabl - specific cellular effect, the method comprising detecting in a MIF and Jabl system an interaction between MIF and Jabl and/or a MIF/Jabl-specific cellular effect in the absence of a candidate drug, and comparing the detected interaction and/or cellular effect to an interaction and/or cellular effect detected in a system containing MIF and Jabl in the presence of a candidate drug and whereby the detected and compared interactions and/or cellular effects are preferably specific MIF/Jabl complex based biological effects. Thus, the present invention is inter alia based on the finding that MIF and Jabl interact, in particular bind to each other and thus form a MIF/Jabl complex. A wide variety of medical applications in which MIF-Jabl-complexes play an important role are encompassed by the present invention e.g. cell growth-related diseases in general, in particular the method of the invention may be used to determine and find drugs for the treatment of MIF- related diseases: endogenous uveitis, proteinuria, glomerulonephritis, wound repair, carcinogenesis, tinnitus, septic shock and arthritis etc.. The interaction between MIF and Jabl demonstrates that a cytokine can modulate cellular regulatory pathways by direct interaction with a transcriptional co-activator. MIF-Jabl interaction provides a molecular basis for prominent activities of MIF. Jabl (c-Jun activation domain binding protein) , in particular p38 Jabl , is a 38K protein originally identified as a specific co-activator of the c-Jun and JunD transcription factors, and which also acts as a negative regulator of the eye1in-dependent- kinase (CDK) inhibitor p27 κipl . A transcriptional co-activator function of Jabl is due to enhancement of AP-1-dependent transcriptional activity. Jabl is a member of the Mov34 family of proteins (Hofmann und Bacher, 1998; Asano et al . , 1997). MIF inhibits enhancement of AP-1 transcriptional activity by Jabl. Jabl is identified to activate c-Jun N- terminal kinase activity (JNK) and this effect is markedly down-regulated by MIF. MIF according to the present invention blocks Jabl- and TNF- mediated activation of JNK. In accordance with the present invention MIF also counter-regulates Jabl dependent cell cycle processes. MIF increases p27 Kιpl expression by stabilisation of p27 Kιpl protein and inhibits Jabl mediated rescue of fibroblasts from starvation induced growth arrest. MIF colo- calises with Jabl in the cytosol and both endoge- nously expressed and exogenous MIF following endocytosis and being targeted to the cytosol bind Jabl in the cytosol. MIF inhibits Jabl- and stimulus- enhanced AP-1 activity, but does not interfere with induction of NFKB. Jabl activates JNK activity and enhances endogenous phospho-c-Jun levels and MIF inhibits these effects. MIF also antagonises Jabl- dependent cell cycle regulation by increasing p27 Kιpl expression through stabilisation of p27 κipl protein. Consequently, Jabl-mediated rescue of fibroblasts from growth arrest is blocked by MIF. Analysis of a MIF peptide consisting only of residues 50-65 of wildtype MIF and of a mutant Cys60 (wildtype MIF with Cys at position 60) shows that region 50 - 65 is important for Jabl binding and modulation. MIF may broadly act to negatively regulate Jabl-controlled pathways and MIF/Jabl interaction could provide a long sought molecular basis for key activities of MIF. MIF broadly acts to negatively regulate Jabl-controlled cellular pathways. The MIF-Jabl interaction provides a molecular basis for key activities of MIF because the MIF-Jabl interaction is connected with pathways and cellular and molecular cycles in the context of MIF-related diseases. In the context of the present invention, a number of general terms shall be utilised as follows. In the context of the present invention, a "MIF- related disease" is a disease such as arthritis, carcinogenesis and/or cancer, nephritis, protein- uria, dermatitis, diabetes/obesity, acute and chronic renal allograft rejection, tubulitis, degeneration of neurones, Parkinson's disease, septic shock, endotoxemia, hypersensitivity, uveitis, tinnitus, wound repair/cell growth; MIF also plays an important role in immunoregulation, inflammation and effector mechanisms of cellular and humoral immunity, septic shock, ocular inflammation, in the regulation of transcriptional and cell cycles, and respiratory distress syndrome, physiological stress and others . In the context of the present invention, the term "drug" refers to a substance being useful for diagnosing and/or treating diseases, in particular MIF- related diseases, preferably in an amount sufficient to obtain such an effect. As used herein, the term "drug" refers both to the active agent itself and the active agent in connection with pharmaceutically acceptable carriers, adjuvants, other active agents, etc. A putative or candidate drug is meant to be a substance or composition to be tested as to whether this substance or composition is suitable to be used as a drug. In a particularly preferred embodiment a „drug" is a small MIF- derived peptide, in particular MIF 50 - 65 or 57 Ser 60 Ser MIF 60 - 65. Thus, the present invention also encompasses the specific peptides which are depicted in SEQ ID No's 1 and 2. In the context of the present invention, the term "treatment" refers to the prophylactic and/or therapeutic effect of a drug. In the context of the present invention, a „MIF and Jabl system" relates to a system in which synthetically produced or naturally occurring MIF and Jabl are present under conditions which permit that they contact each other and bind, either under natural or artificial conditions. In one embodiment of the present invention, a MIF and Jabl system is a naturally occurring cell or a recombinantly produced cell . In another embodiment of the present invention, a MIF and Jabl system may be a crude extract made from the above cells or made from other sources, as long as they contain MIF and Jabl. In another embodiment of the present invention, a MIF and Jabl system is for instance an in vitro translation system containing elements allowing the production or purification of pure or semi-pure MIF and Jabl or of fusion or complex proteins comprising all or a part of MIF and Jabl, each alone or together. In the context of the present invention, the term "MIF" relates to naturally occurring MIF as well as to any modifications, mutants or derivatives of MIF such as recombinantly produced MIF containing amino acid modifications, such as inversions, deletions, insertions, additions, etc., as long as at least part of the essential biological functions of wildtype MIF are present. Such a MIF may also comprise unusual amino acids and/or modifications such as alkylation, oxidation, thiol-modification, de- naturation, and oligomerisation and the like. In particular, in the context of the present invention, a MIF may be a protein, in particular a fusion protein containing all or part of the MIF in addition to other proteins, peptides or parts thereof . In a further embodiment of the present invention, the MIF is a truncated version of the naturally occurring MIF, such as a small peptide. In a particularly preferred embodiment of the present invention, such a small peptide is a MIF peptide fragment such as MIF 50 - 65 (peptide consisting of wildtype amino acid sequence residues 50 - 65 (SEQ ID No. 1) or Ser 57 Ser 50 MIF 50 - 65 (wildtype amino acid residues 50 - 65 except for the replacement of wildtype Cys 57 and Cys 60 by Ser 57 and Ser 60 .) Both of these peptides are subject matter of the present teaching. In the context of the present invention, the term "Jabl" relates to naturally occurring Jabl as well as to any modifications, mutants or derivatives of Jabl such as recombinantly produced Jabl containing amino acid modifications, such as inversions, deletions, insertions, additions, etc., as long as at least part of the essential biological functions of wildtype Jab are present. Such a Jabl may also comprise unusual amino acids and/or modifications such as alkylation, oxidation, thiol-modification, denaturation, and oligomerisation and the like. In particular, in the context of the present invention, a Jabl may be a protein, in particular a fusion protein containing all or part of the Jabl in addition to other proteins, peptides or parts thereof . In a further embodiment of the present invention, the Jabl is a truncated version of the naturally occurring Jabl such as the so-called MPN domain or Mov-34 domain (Asano et al . , 1997; Hof- mann and Bacher, 1998) or a small peptide. The term "promoter" refers to a sequence of DNA, usually upstream (5') to the coding sequence of a structural gene, which controls the expression of the coding region by providing the recognition for RNA polymerase and/or other factors required for transcription to start at the correct site. Promoter sequences are necessary, but not always sufficient to drive the expression of the gene. "Nucleic acid" refers to a large molecule which can be single or double stranded, composed of monomers (nucleotides) containing a sugar, phosphate and either a purine or pyrimidine . The nucleic acid may be cDNA, genomic DNA, or RNA, for instance mRNA. The term "nucleic acid sequence" refers to a natural or synthetic polymer of DNA or RNA which may be single or double stranded, alternatively containing synthetic, non-natural or altered nucleotide bases capable of incorporation into DNA or RNA polymers. The term "gene" refers to a DNA sequence that codes for a specific protein and regulatory elements controlling the expression of this DNA sequence. The term "coding sequence" refers to that portion of a gene encoding a protein, polypeptide, or a portion thereof, and excluding the regulatory sequences which drive the initiation or termination of transcription. The coding sequence and/or the regulatory element may be one normally found in the cell, in which case it is called "autologous" or "endogenous", or it may be one not normally found in a cellular location, in which case it is termed "heterologous" . A heterologous gene may also be composed of autologous elements arranged in an order and/or orientation not normally found in the cell in which it is transferred. A heterologous gene may be derived in whole or in part from any source known to the art, including a bacterial or viral genome or episome, eucaryotic nuclear or plasmid DNA, cDNA or chemically synthesised DNA. The structural gene may constitute an uninterrupted coding region or it may include one or more introns bounded by appropriate splice junctions. The structural gene may be a composite of segments derived from different sources, naturally occurring or synthetic. A "transactivator protein" is a protein that can bind to the operator region of a gene and thereby promote transcription of the gene. A "DNA-binding domain" is a sequence of amino acids that are capable of binding to a specific DNA sequence . A "fusion protein" is a protein made up of amino acid sequences derived from at least two different sources. In the context of a fusion protein, a "heterologous" amino acid sequence is a sequence originating from a source different from other parts of the fusion protein. A "detectable gene product" is a nucleotide or amino acid sequence that can be detected by an assay. Preferably, the expression of a detectable gene product confers a characteristic on a cell that allows the cell to be conveniently selected among other cells that do not express the detectable gene product . By "operably linked" or "under operational control" it is meant that a gene and a regulatory sequence are connected in sense or antisense expression in such a way as to permit gene expression when the appropriate molecules (e.g. transcriptional activator proteins) are bound to the regulatory sequence. The term "associated" in the context of the present invention refers to any type of interaction between MIF and Jabl, in particular covalent or noncovalent binding or association such as, but not limited to, a covalent bond, hydrophobic/hydrophilic interaction, van der aals forces, ion pairs, ligand-receptor interaction, epitope- antibody binding site interaction, enzyme-substrate interaction, liposome-hydrophobic interaction, nucleotide base pairing, membrane-hydrophobic interaction, and the like. Such an association may also include the presence of further molecules, such as peptides, proteins, such as Kip, Jun, c-Jun-amino- terminal kinase (JNK) , steroid receptor coactivator 1 (SRC-1) , integrin LFA-1, progesterone receptor (PR) or glucocorticoide receptor (GR) , or nucleotide sequences . The term "vector" refers to a recombinant DNA construct which may be a plasmid, virus, or autonomously replicating sequence, phage or nucleotide sequence, linear or circular, of a single or double stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product in sense or antisense orientation along with an appropriate 3' untranslated sequence into a cell. "Plasmids" are genetic elements that are stably inherited without being a part of the chromosome of their host cell. They may be comprised of DNA or RNA and may be linear or circular. Plasmids code for molecules that ensure their replication and stable inheritance during cell replication and may encode products of considerable medical, agricultural and environmental importance. For example, they code for toxins that greatly increase the virulence of pathogenic bacteria. They can also encode genes that confer resistance to antibiotics. Plasmids are widely used in molecular biology as vectors to clone and express recombinant genes. Plasmids are generally designated herein by a lower case p preceded and/or followed by upper-case letters and/or numerals, in accordance with standard naming conventions familiar to those of skill in the art. Starting plasmids disclosed herein are either commercially available, publicly available, or can be constructed from available plasmids by routine application of well known, published procedures. Many plasmids and other cloning and expression vectors that can be used in accordance with the present invention are well known and readily available to those of skill in the art. Moreover, those of skill readily may construct any number of other plasmids suitable for use in the invention. The properties, construction and use of such plasmids, as well as other vectors, in the present invention will be readily apparent to those of skill from the present disclosure. The term "expression" as used herein is intended to describe the transcription and/or coding of the sequence for the gene product. In the expression, a DNA chain coding for the sequence of gene product is first transcribed to a complementary RNA, which is often an mRNA, and then the thus transcribed mRNA is translated into the above mentioned gene product if the gene product is a protein. However, expression also includes the transcription of DNA inserted in antisense orientation to its regulatory elements. Expression, which is constitutive and possibly further enhanced by an externally controlled promoter fragment thereby producing multiple copies of mRNA and large quantities of the se- lected gene product, may also include overproduction of a gene product. The term "host cell" refers to a cell which has been genetically modified by transfer of a chi- meric, heterologous or autologous nucleic acid sequence or its descendants still containing this sequence. These cells are also termed "transgenic cells" . In the case of an autologous nucleic acid sequence being transferred, the sequence will be present in the host cell in a higher copy number, in a different orientation and/or at a different place than naturally occurring. The term "MIF-Jabl-complex" refers to an association of MIF and Jabl, e.g. an interaction between domains of MIF and Jabl . The term "target activity" refers to a MIF-Jabl- complex induced activity, e.g. an expression of a reporter gene or a regulation of an AP-1 activity or a regulation of CDK (cyclin-dependent kinases) inhibitors or other MIF-Jabl-specific target activities . The proteins of the invention that do not occur in their natural (cellular) environment are isolated. The term "isolated" as used herein, in the context of proteins, refers to a polypeptide which is unaccompanied by at least some of the material with which it is associated in its natural state. The isolated protein constitutes at least 0.5%, preferably at least 5%, more preferably at least 25% and still more preferably at least 50% by weight of the total protein in a given sample. Most preferably the "isolated" protein is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated, and yields a single major band on a non-reducing poly- acrylamide gel. Substantially free means that the protein is at least 75%, preferably at least 85%, more preferably at least 95% and most preferably at least 99% free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated. "Affinity chromatography" is known to involve separation of proteins by selective absorption onto and/or elution from a solid medium or a solid support (e.g. immobilised Jabl, immobilised MIF, immobilised anti-MIF-Jabl-domain antibodies and/or immobilised anti-MIF-Jabl-fusion-protein antibodies etc.) , generally in the form of a column. The solid medium is usually an inert carrier matrix to which is attached a ligand having the capacity to bind under certain conditions with the required protein or proteins in preference to others present in the same sample, although in some cases the matrix itself may have such selective binding capacity. The ligand may be biologically complementary to the protein to be separated, for example, antigen and antibody, or may be any biologically unrelated molecule which by virtue of the nature and steric relationship of its active groups has the power to bind the protein. The support matrices commonly used in association with such protein- binding ligands include, for example, polymers and copolymers of agarose, dextrans and amides, espe- cially acrylamide, or glass beads or nylon matrices. Cellulose and substituted celluloses are generally found unsuitable when using dyes, since, although they bind large amounts of dye, the dye is poorly accessible to the protein, resulting in poor protein binding. By "solid support" an insoluble matrix is meant, either biological in nature, such as, without limitation, a cell or bacteriophage particle, or synthetic, such as, without limitation, an acrylamide derivate, cellulose, nylon, silica and magnetised particles, to which soluble molecules may be linked or joined. "Antibody" refers to a polypeptide substantially encoded by an immunoglobulin gene or immunoglobulin genes, or fragments thereof, which specifically bind and recognise an analyte (antigen) . The recognised immunoglobulin genes include the kappa, lambda, alpha, gamma, delta, epsilon and mu constant region genes, as well as the myriad immunoglobulin variable region genes. Antibodies exist, e.g., as intact immunoglobulins or as a number of well characterised fragments produced by digestion with various peptidases. "Antibody" also refers to modified antibodies (e.g. oligomeric, reduced, oxidated and labelled antibodies) . The term "antibody", as used herein, also includes antibody fragments either produced by the modification of whole antibodies or those synthesised de novo using recombinant DNA methodologies. The term "antibody" includes intact molecules as well as fragments thereof, such as Fab, F(ab') 2 , and Fv which are ca- pable of binding the epitopic determinant . These antibody fragments retain some ability to selectively bind with its antigen or receptor and are defined as follows: (1) Fab, the fragment which contains a monovalent antigen-binding fragment of an antibody molecule can be produced by digestion of whole antibody with the enzyme papain to yield an intact light chain and a portion of one heavy chain; (2) Fab' , the fragment of an antibody molecule can be obtained by treating whole antibody with pepsin, followed by reduction, to yield an intact light chain and a portion of the heavy chain; two Fab' fragments are obtained per antibody molecule; (3) (Fab') 2 , the fragment of the antibody that can be obtained by treating whole antibody with the enzyme pepsin without subsequent reduction; F(ab') 2 is a dimer of two Fab 1 fragments held together by two disulfide bonds; (4) Fv, defined as a genetically engineered fragment containing the variable region of the light chain and the variable region of the heavy chain expressed as two chains; and (5) Single chain antibody ("SCA"), defined as a genetically engineered molecule containing the variable region of the light chain, the variable region of the heavy chain, linked by a suitable polypeptide linker as a genetically fused single chain molecule . Methods of making these fragments are known in the art. (See for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1988) ) . As used in this invention, the term "epitope" means any antigenic determinant on an antigen to which the paratope of an antibody binds. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three dimensional structural characteristics, as well as specific charge characteristics. Monoclonal antibodies to the proteins of the present invention, and to the fragments thereof, can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies by using hybridoma technology is well known. Immortal antibody-producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., M. Schreier et al . , "Hybridoma Techniques" (1980); Hammerling et al . , "Monoclonal Antibodies and T-cell Hybridomas" (1981) ; Kennett et al., "Monoclonal Antibodies" (1980); see also U.S. Pat. Nos. 4,341,761; 4,399,121; 4,427,783; 4,444,887; 4,452,570; 4,466,917; 4,472,500; 4,491,632; and 4,493,890. Panels of monoclonal antibodies produced against the protein of interest, or fragment thereof, can be screened for various properties; i.e., for isotype, epitope, affinity, etc. Alternatively, genes encoding the monoclonals of interest may be isolated from the hybridomas by PCR techniques known in the art and cloned and expressed in the appropriate vectors. Monoclonal antibodies are useful in purification, using immu- noaffinity techniques of the individual proteins against which they are directed. The antibodies of this invention, whether polyclonal or monoclonal, have additional utility in that they may be employed as reagents in immunoassays, RIA, ELISA, and the like. In addition, they can be used to isolate the MIF, Jabl, MIF-Jabl domain etc. from cells. The antibodies e.g. could be used to establish a tissue culture based assay for discovery or modification of novel compounds which block the interaction of MIF and Jabl. The humanised or chimeric antibodies can comprise portions derived from two different species (e.g., human constant region and murine binding region) . The portions derived from two different species can be joined together chemically by conventional techniques or can be prepared as a single fusion protein using genetic engineering techniques. DNA encoding the proteins of both portions of the chimeric antibody can be expressed as a single fusion protein. An antibody "specifically binds to" or "is specifically immunoreactive with" a protein when the antibody functions in a binding reaction which is determinative of the presence of the protein in the presence of a heterogeneous population of proteins and other biologies. Thus, under designated immu- noassay conditions, the specified antibodies bind preferentially to a particular protein and do not bind in a significant amount to other proteins present in the sample. Specific binding to a protein under such conditions requires an antibody that is selected for its specificity for a particular protein. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein. For example, solid- phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity. "Immunoassay" refers to an assay that utilises an antibody to specifically bind an analyte . The immunoassay is characterised by the use of specific binding properties of a particular antibody to isolate, target, and/or quantify the analyte. In a preferred embodiment of the present invention, the method for drug-screening is an in vitro method. In a particularly preferred embodiment of the present invention, the in vitro method for drug- screening is an assay for detecting the interaction, in particular binding between MIF and Jabl. In a preferred embodiment of the present invention, the MIF-Jabl binding is measured by using conventional methods of radioactive labelling, photo la- belling, fluorescence labelling, biotin labelling, co-precipitation, immunoprecipitation, fractiona- tion by chromatography etc. of MIF, Jabl and/or the complex thereof in the presence or absence of a drug to be screened. In particular, the present invention relates to so- called HTP methods, this means high throughput screening methods. In accordance with one embodiment of the present invention, MIF/Jabl binding may be tested in the presence or absence of a competitive peptide which competes with MIF or Jabl for the respective binding partner, i.e. MIF or Jabl. In particular, such a competitive binding partner may be a MIF derived analogue, for instance, a mutant of MIF, e.g. a fragment of MIF such as a peptide fragment consisting of amino acid residues 50 - 65 of wildtype human MIF or a peptide fragment consisting of wildtype amino acid residues 50 - 65 of human MIF except that at positions 57 and 60, with respect to the wildtype numbering (Kleemann et al . , 1998 b) the natural occurring amino acids have been replaced by Ser. Thus, these truncated 16 amino acid residues long MIF peptides are, according to the present invention, very useful MIF competitive peptides which might be used in the present assay systems. In particular, in a further preferred embodiment of the present invention, MIF/Jabl binding can be tested in the presence or absence of such a competitive peptide, while simultaneously, a candidate drug is also present to be tested for its effects on MIF/Jabl interaction. In another preferred embodiment the above identified MIF truncated peptides may serve itself as candidate drugs, i.e. eventually as drugs. Such a competitive binding partner may also be a Jabl derived analogue, for instance, a mutant of Jabl or a fragment of Jabl such as a domain or peptide fragment of wildtype human or mouse Jabl. Such truncated Jabl proteins or peptides are, according to the present invention, very useful Jabl competitive molecules which might be used in the present assay systems. In particular, in a further preferred embodiment of the present invention, MIF/Jabl binding can be tested in the presence or absence of such a competitive Jabl peptide, while simultaneously, a candidate drug is also present to be tested for its effects on MIF/Jabl interaction. In another preferred embodiment these Jabl truncated molecules may serve itself as candidate drugs, i.e. eventually as drugs. In a preferred embodiment of the present invention, the binding between MIF and Jabl can, for instance, be explored by co-precipitation: MIF is immobilised on beads either covalently or non-covalently via e.g. binding of GST-MIF to GSH-beads or biotin-MIF to Streptavidin beads or MBP-MIF to malate beads (MBP: malate binding protein) and incubated with soluble Jabl in the absence (control) and presence of candidate drugs . The suspension is washed and the amounts of Jabl bound to the solid phase are detected by Western-Blot or the like following elution of Jabl from the complex or Jabl is detected in the supernatant; the amounts of Jabl in the presence and absence of candidate drugs are compared. The binding between Jabl and MIF can also, for instance, be investigated by co-precipitation: Jabl is immobilised on beads and incubated with soluble MIF in the absence (control) and presence of drugs. Jab may be bound either covalently or non- covalently to the beads via e.g. binding or binding of GST-Jabl to GSH-beads or biotin-Jabl to Streptavidin beads or binding of MBP-Jabl to malate beads. The suspension is washed and the amounts of MIF bound to the solid phase are detected e.g. by Western-Blot or the like following eluation of MIF from the complex or MIF is detected in the supernatant; the amounts of MIF in the presence and absence of putative or candidate drugs are compared. The general concept of these co-precipitation embodiments is incubation of two partners, for instance Jabl and MIF, whereby one partner, for instance MIF, is covalently bound to GST. The two partners, MIF-GST and Jabl were incubated in the presence of a solid phase, for instance GSH-beads. In this way the complex of MIF and Jabl can bind to the GSH-beads because a non-covalent binding between GSH and GST which is covalently bound to MIF occurs. The suspension of solid phase-GSH-beads- and the non-covalent bound complex of GST-MIF which is non-covalent bound to Jabl is washed and then Jabl is eluated by boiling in SDS buffer. The supernatant of the suspension is separated by SDS- PAGE. The SDS gel is blotted by Western-Blot and Jabl is detected on the blot by anti-Jabl antibodies . From this general concept various embodiments are preferred: (i) GSH-beads were incubated with GST-MIF and Jabl; and Jabl bound to GSH-beads via GST- MIF (see above) is detected with anti-Jabl antibodies by Western-Blot, (ii) MIF-beads were incubated with Jabl; and Jabl bound to the MIF-beads is detected with anti-Jabl antibodies by Western-Blot, (iii) GSH-beads were incubated with GST-Jabl and MIF; and MIF bound to GSH-beads via GST- Jabl is detected with anti-MIF antibodies by Western-Blot, (iv) Jabl-beads were incubated with soluble MIF; and MIF bound to Jabl-beads is detected with anti-MIF antibodies by Western-Blot, (v) Malate-beads were incubated with MBP-MIF and Jabl; and Jabl bound to Malate-beads via MBP-MIF is detected with anti-Jabl antibodies by Western-Blot, (vi) Malate-beads were incubated with MBP-Jabl and MIF; and MIF bound to Malate-beads via MBP-Jabl is detected with anti-MIF antibodies by Western-Blot, (vii) Protein A-beads were incubated with anti- MIF antibodies and MIF and biotin-Jabl; and streptavidin bound to Protein A beads is detected by Western-Blot, (viii) Protein A-beads were incubated with anti- MIF antibodies and MIF and Jabl; and Jabl bound to Protein A beads is detected with anti-Jabl antibodies by Western-Blot and (ix) Dynalbeads-streptavidin were incubated with biotin-EGFP-MIF and Jabl; and Jabl bound to Dynalbeads-streptavidin is detected with anti-Jabl antibodies by Western-Blot. The screening for drugs interfering with the MIF/Jabl-interaction can also be done by a protein array, e.g. on a so-called biochip. For instance MIF is immobilised on a solid support, for example a polymeric support or silica wafer or glass slide or nylon membrane, either covalently or non- covalently via e.g. binding of GST-MIF to a solid GSH-support or biotin-MIF to a solid Streptavidin- support or MBP-MIF to a solid malate-support . In accordance with known methods MIF can also be directly immobilised on a solid support via amino acid residues such as Lys or Cys or similar amino acid residues or via non-natural amino acids, whereby no additional tag molecules are needed. The immobilised MIF protein is then incubated with soluble Jabl in the absence (control) or presence of candidate drugs. The influence of a candidate drug on the interaction between MIF and Jabl can then be detected by methods such as fluorescence or MALDI-MS detection methods. In another embodiment Jabl or Jabl-derived domain is immobilised on a solid support either covalently or non-covalently via binding of GST-Jabl to a GSH-support or biotin- Jabl to a Streptavidin-support or binding of MBP- Jabl to a malate-support or direct covalent binding of Jabl without additional tag molecules via amino acid residues such as Lys or Cys or via non-natural amino acids. The immobilised Jabl protein is then incubated with soluble MIF in the absence or presence of candidate drugs, whereby the influence of the candidate drugs on the interaction between MIF and Jabl is detected by fluorescence or MALDI-MS methods . The materials used in biochips as supports for MIF or Jabl can comprise any polymeric materials, for example nylon. These polymeric supports can themselves be fixed on a porous mineral support comprising, for example, a metallic oxide such as silica, alumina, magnesia, etc., or natural or synthetic derivatives of these oxide such as glasses, silicates, borosilicates, kaolin etc. The said polymers can be fixed on the porous mineral support by impregnation, the polymer coating then being, if necessary, stabilised by crosslinking in accordance with known methods. The crosslinking agent is, for example, a dicarbonyl compound, a halohydrin, a diepoxide, etc. The polymer supports can also be fixed on mineral supports by means of an intermediate bifunctional coupling agent. The desialyled proteins can also be fixed on the polymeric support by means of an appropriate bifunctional coupling agent, in accordance with known methods. The cou- pling agents are, for example, bifunctional derivatives such as cyanogen bromide, dialdehydes, diepoxides, etc. The proteins can also be directly fixed on the porous mineral support. For example, in the case of a silica support, an aminoalkyl- silane derivative of silica, is prepared and the desialyled protein is fixed on the aminoalkylsilane using a bifunctional agent such as glutaraldehyde; see for example P. J. Robinson et al, Biochem. Biophys. Acta, 242, 659-661 (1971) . The desialyled proteins can also be fixed on porous mineral supports in accordance with the method described in French patent application 77.28163 (publication No. 2.403.098). This process comprises coating a porous mineral support with a polymer capable of undergoing a cleavage reaction oxidising the glycol groups using oxidising agents such as periodates . A polycarbonyl coating is obtained and the ligand, for example, the desialyled glycoprotein, can then be fixed on the carbonyl groups formed. If desired, the imine group formed can be reduced to the amine . In a preferred embodiment, the method for testing the interaction, e.g. binding of MIF and Jabl, is an electromobility shift assay. The MIF-Jabl binding reduces or enhances the flexibility/mobility of the c-Jun/DNA or Jabl/c-Jun/DNA complexes in a gel (for instance native polyacrylamide gel) . Shifts of the DNA probe alone or as part of a complex in the gel in the absence or presence of candidate drugs can be detected by radioactive or fluorescence labelling of the DNA probe. In accordance with the present invention the method for detecting MIF-Jabl binding also comprises an array of proteins: MIF-Jabl protein binding reduces or enhances the flexibility/mobility of MIF and Jabl in a gel (e.g. native polyacrylamide gel) . Shifts of the proteins (MIF, Jabl, MIF-Jabl- complex) in the gel in the absence and presence of candidate drugs can be detected by radioactive or fluorescence labelling of MIF and/or Jabl. In a preferred embodiment of the present invention, the method for detecting the MIF-Jabl binding by chromatography also comprises absorbing the MIF in the absence and presence of candidate drugs onto a Jabl-chromatographic support, and washing the column with buffer and detecting the MIF in the eluate or bound MIF directly; e.g. the amount of MIF in the eluate is higher in the presence than in the absence of the candidate drug, if the candidate drug is a dissociator. The method for detecting the MIF-Jabl binding by chromatography also comprises absorbing the Jabl in the absence and presence of candidate drugs onto a MIF-chromatographic support, immobilised anti-MIF-Jabl-domain antibodies and/or immobilised anti-MIF-Jabl-fusion protein antibodies etc. and washing the column with buffer and detecting the Jabl in the eluate; for instance the amount of Jabl in the eluate is lower in the presence than in the absence of the candidate drug, if the candidate drug is not a dissociator. The method for detecting the MIF-Jabl binding also comprises adsorbing the soluble MIF of Jab in the absence or presence of candidate drugs onto a MTP (microtiter plate) or biochip with immobilised MIF or Jabl . In a particularly preferred embodiment of the present invention, MIF and/or Jabl to be used is obtained by in vitro translation. In another preferred embodiment MIF and Jabl are contained in crude or partially purified cell extracts. Cell extracts encompassed by the present invention are biological tissue, or liquids or suspensions with cells or fragments thereof. Such cell extracts may be obtained by mechanical agitation or shearing, by sonification, by applying electrical fields, by applying chemical and/or enzymatic agents, etc. to cell or tissues. The present invention also includes any combination of the "in vitro" and "cell extract" methods; e.g. MIF and Jabl are contained in a suspension, whereby Jabl is contained in a cell-extract and pure MIF is bound on beads . In another preferred embodiment, the method for testing the interaction, in particular binding of MIF and Jabl, is an in vivo method. The in vivo method is widely recognised as a particularly reliable measure of the biological activity of the MIF- Jab interaction. Since the in vivo methods of the invention do not involve a potentially toxic metabolism, these methods are particularly useful as a diagnostic tool in measuring interaction of MIF and Jabl in vivo. In comparison to in vitro methods, the in vivo methods are safe, more widely applicable, more easily performed, more sensitive, produce more accurate results and more reliably to represent the physiological situation. Labelling of MIF and/or Jabl is accomplished via physiologic substrates rather than potentially toxic, non- physiological metabolites; preservation of the cell and tissue anatomy is not required; and no radioactivity is involved. The present invention also encompasses with respect to MIF and Jabl genetically manipulated, in particular transgenic animals, especially mammals, in particular mice and cells thereof. These animals, containing in at least some of their cells for instance, transfected sense or antisense constructs of MIF and Jabl coding sequences under control of regulatory elements, in particular so called knockout-animals, are useful for research and diagnosis because the activity of MIF, Jabl or the MIF-Jabl interaction is modified. The modification of MIF, Jabl or of the MIF-Jabl complex in transgenic animals is possible e.g. by using sense or antisense nucleotide sequences of MIF, Jabl or MIF-Jabl fusions, or any modifications of these nucleotide sequences such as inversions, deletions, insertions, additions, etc. to transform and obtain such animals genetically manipulated in both loci, namely MIF and Jabl. Thus, the present invention also relates to animals being genetically modified, in particular being transgenic animals which exhibit a modified MIF and Jabl expression in contrast to the wildtype animal. Such a modified expression in a mammalian, in particular a non-human mammalian cell may be due to the introduction of MIF and/or Jabl antisense or sense constructs, possibly containing nucleotide sequence alteration and/or may be due to manipulations in the endogenous nucleotide sequences for the MIF and Jabl protein. By virtue of these modifications such as insertions of additional mutated or non-mutated sense or antisense copies of MIF and Jabl or modifications in the endogenous genes, including modifications in the regulatory regions, it is possible to obtain useful animals for the above-identified purposes. The present invention thus also relates to single non- human mammalian cells or cell cultures containing the above identified modifications. In a preferred embodiment of the present invention the in vivo method comprises a) providing a cell over-expressing MIF and/or Jabl, b) detecting expression of a MIF-Jabl-complex target activity, in particular the activity of a reporter gene in the absence of a candidate drug, c) detecting expression of the MIF-Jabl-complex target activity, in particular the activity of a reporter gene in the presence of the candidate drug and d) comparing the results obtained in b) and c) . In a preferred embodiment of the present invention, the reporter gene is capable of being induced by the MIF-Jabl-complex, e.g. providing binding and effector sites near or at the regulatory sites of the reporter gene and is capable of expressing a gene product coded by the coding region of the reporter gene which, in turn, may be detected directly or indirectly by detection means and methods . The present invention also relates to a method wherein the cell over-expressing MIF and/or Jabl is obtained by transfecting a host cell with: a) a vector comprising a MIF coding sequence under operational control of a promoter, a vector comprising a Jab coding sequence under operational control of a promoter, a vector comprising the reporter gene or b) a vector containing the MIF and Jabl coding gene under the operational control of a single promoter and a vector comprising the reporter gene, or c) a vector containing MIF and Jabl coding sequence and the reporter gene under the operational control of the single promoter. In a particularly preferred embodiment, the promoter is a strong constitutive or inducible promoter such as CMV or Tet. By creating bicistronic or multicistronic constructs which contain MIF, Jabl and/or reporter genes a coupled expression of MIF, Jabl and/or reporter genes is allowed. In particular, molecular elements or factors separate genes in a manner that fusion proteins can be prevented. In a particularly preferred embodiment of the present invention, the reverse two-hybrid-method for determining whether a candidate drug disrupts binding between MIF and Jabl comprises : a) providing a cell containing i) a reporter gene, operably linked to a DNA binding protein recognition site; ii) a first fusion gene expressing a first hybrid protein comprising MIF covalently bonded to a DNA-binding moiety which specifically binds to DNA-binding protein recognition site; and iii) a second fusion gene expressing a second hybrid protein comprising Jabl covalently bonded to a gene activating moiety, wherein Jabl binds MIF in the absence of drug; b) contacting the cell with the candidate drug under conditions allowing expression of the reporter gene; and c) detecting inhibition of expression of the reporter gene as a measure of the ability of the candidate drug to disrupt binding between MIF and Jabl . The invention permits the identification of molecules which dissociate or prevent interaction or binding between MIF and Jabl . The candidate drugs which potentially disrupt binding between MIF and Jabl - the so-called dissociator compounds - can for instance be introduced into cells by simply adding them to cultures. By "dissociator compounds" any molecule is meant which disrupts, prevents or modulates interaction, in particular the binding of MIF and Jabl. Examples of dissociator compounds are polypeptides, nucleic acids, organic and anorganic molecules and ions. Many potential dissociator compounds are small enough that they will be taken up by a cell by endocytosis or diffusion through the membrane, if sufficiently hydro- phobic. Alternatively, if the dissociator compound is an RNA molecule or a protein, it can be produced in a cell by transforming the cell with the corresponding DNA construct and expressing the desired RNA or protein. Compounds which stabilise molecular interactions between MIF and Jabl can also be identified by these methods. A method for detecting the interaction between MIF and Jabl is also provided in accordance with the present invention. The method comprises providing a host cell, preferably a procaryotic or eucaryotic cell. The host cell contains a detectable reporter gene having a binding site for a DNA-binding domain of the transcriptional activator, such that the detectable gene expresses a detectable protein when the detectable gene is transcriptionally activated. Such activation occurs when the transcriptional activation domain of a transcriptional activator is brought into sufficient proximity to the DNA- binding domain of the transcriptional activator. A first chimeric gene is provided which is capable of being expressed in the host cell. A chimeric molecule is a molecule in which two or more molecules that exist separately in their native state are joined together to form a single molecule having the desired functionality of all its constituent molecules . While the chimeric molecule may be prepared by covalently linking two molecules, each of which are synthesised separately, one of skill in the art will appreciate that where the chimeric molecule is a fusion protein, the chimera may be prepared de novo as a single "joined" molecule, i.e. by genetic engineering methods. The first chimeric gene may be present in a chromosome or plasmid of the host cell. The first chimeric gene comprises a DNA sequence that encodes a first hybrid protein. The first hybrid protein contains a DNA-binding domain that recognises the binding side on the reporter gene in the host cell. The first hybrid protein also contains a MIF protein or a MIF protein fragment which is to be tested for interaction with a Jabl protein or Jabl protein fragment. A second chimeric gene is provided which is capable of being expressed in the host cell. In one embodiment, both the first and the second chimeric genes are introduced into the host cell in the form of plasmids. Preferably, however, the first chimeric gene is present in the chromosome of the host cell and the second chimeric gene is introduced into the host cell as part of a plasmid. The sec- ond chimeric gene contains a DNA sequence that encodes a second hybrid protein. The second hybrid protein contains a transcriptional activation domain. The second hybrid protein also contains a Jab protein or a Jab protein fragment which is to be tested for interaction with the MIF protein or MIF protein fragment . The DNA-binding domains of the first hybrid protein and the transcriptional activation domain of the second hybrid protein are preferably derived from transcriptional activators having separate DNA-binding and transcriptional activation domains. These separate DNA-binding and transcriptional activation domains are for example known to be found in the yeast GAL4 protein, and are also known to be found in the yeast GCN4 and ADR1 proteins. Numerous other proteins involved in transcription also have separate binding and transcriptional activation domains which make them useful for the present invention. In another embodiment, the DNA-binding domain and the transcriptional activation domain may be from different transcriptional activators. The second hybrid protein may be encoded on the library of plasmids that contain genomic, cDNA or synthetically generated DNA sequences fused to the DNA sequence encoding the transcriptional activation domain. A variety of DNA-binding moieties and gene activating moieties are suitable for use in the various aspects of the invention. Generally, the DNA- binding domain or gene activating domain of any transcription factor can be used. If desired, the gene activating domain of VP16 can be used. The DNA-binding-protein recognition site and the gene activating and DNA-binding moieties all can correspond to identical transcription factors, or they can correspond to different transcription factors. Useful binding sites include those for the yeast protein GAL4 , the bacterial protein LexA, the yeast metal-binding factor Acel. These binding sites can readily be used with a repressed promoter (e.g. a SP013 promoter can be used as the basis for SPAL, SPEX and SPACE promoters, respectively, for a SP013 promoter combined with GAL, LEX and ACE1 DNA binding sites) . Other useful transcription factors include the GCN4 protein of S. cerevisiae (see e.g., Hope and Struhol, 1986. Cell 46:885-894) and the ADR1 protein of S. cerevisiae (see, e.g., Kumar et al., 1987, Cell 51:941-951). The DNA-binding protein recognition site should include at least one binding site for the binding domain of the transcription factor that is used. While the number of DNA-binding-protein recognition sites that can be used is unlimited, the number of binding sites is preferably between 1 and 100, more preferably 1 and 20; still more preferably, the number of binding sites is between 1 and 16. The number of binding sites can be adjusted to account for factors such as the desired selectivity or sensitivity of the assay. The interaction between the MIF protein or parts thereof and the Jabl protein or parts thereof in the host cell, therefore, causes the transcriptional activation domain to activate transcription of the reporter gene. The method is carried out by introducing the first chimeric gene and the second chimeric gene into the host cell . The host cell is subjected to conditions under which the first hybrid protein and the second hybrid protein are expressed in sufficient quantity for the reporter gene to be activated. The cells are then tested for expression of the reporter gene to a greater degree than in the absence of interaction between the MIF protein and the Jabl protein. In a preferred embodiment of the invention, the expression of the reporter gene is determined in host cells subjected to a candidate drug to be screened and compared to the expression of the reporter gene in host cells not subjected to the candidate drug. In a preferred embodiment the invention relates to a DNA-binding domain and transcriptional activation domain, which are derived from transcriptional activators having separable DNA-binding and transcriptional activation domains. In a further preferred embodiment of the invention, the DNA-binding domain in the transcriptional activation domain is selected from the group consisting of the transcriptional activators GAL4 , GCN4 and ADR1. The system is dependent upon a number of conditions to properly carry out the method of this invention. The interacting MIF protein must not itself carry an activation domain for the marker. The activation domain would otherwise allow transcription of the marker gene as soon as the vector encoding only the GAL4 DNA-binding domain fused to the MIF protein is introduced. The interaction between the MIF protein and the Jabl protein must be capable of occurring within the yeast nucleus. The GAL4 activation domain portion of the hybrid containing the Jabl protein must be accessible to the transcription mechanism of the cell to allow transcription of the marker or reporter gene. Should any of these conditions not exist, the system may be modified for use by constructing hybrids that carry only portions of the interacting proteins MIF and Jabl, and thus meet these conditions. Since other eucaryotic cells use a mechanism similar to that of yeast for transcription, other eucaryotic cells can be used instead of yeast to test for the interaction of MIF and Jabl, such as mammalian cells. The reporter gene function can be served by any of a large variety of genes, such as genes encoding resistance or metabolic enzymes or GFP (green-fluorescent protein) . The function of GAL4 can be served by any transcriptional activator that has separable domains for DNA-binding and for transcriptional activation. Any protein, including one which is not a transcriptional activator but which has two separable functions, can be used to establish a similar genetic system to detect the MIF- Jabl interactions. Accordingly, the method of the present invention can be applied more generally to any detectable function requiring separable domains of an amino acid sequence which can be reconstituted. This general embodiment of the present invention detects interactions between MIF and Jabl . The method includes providing a host cell which is defective in a detectable function. The detectable function is restored/provided by an amino acid sequence having separable domains. Thus, the amino acid sequence includes first and second domains which are capable of producing the detectable function when they are in sufficient proximity to each other within the host cell. In a particularly preferred embodiment of the present invention, the first hybrid protein and/or the second hybrid protein is encoded on a the library of plasmids containing DNA inserts derived from the group consisting of genomic DNA, cDNA and synthetically generated DNA. In a further preferred embodiment of the present invention the chimeric genes are introduced into the host cells in the form of plasmids. In a particularly preferred embodiment of the present invention a first chimeric gene is provided that is capable of being expressed in the host cell. The first chimeric gene includes a DNA sequence that encodes a first hybrid protein. The first hybrid protein contains a first domain of the amino acid sequence. The first hybrid protein also contains a MIF protein or protein fragment which is to be tested for interaction with a Jabl protein or Jabl protein fragment . In another embodiment of the present invention the first chimeric gene is integrated into the chromosomes of the host cell, and the second chimeric gene is introduced into the host cell as part of a plasmid. A second chimeric gene is provided which is capable of being expressed in the host cell. The second chimeric gene contains a DNA sequence that encodes a second hybrid protein. The second hybrid protein contains a second domain of the amino acid sequence. The second hybrid protein also contains a Jabl protein or fragment which is to be tested for interaction with the MIF protein or the MIF protein fragment. The interaction between the MIF protein and the Jabl protein in the host cell causes a function of the amino acid sequence to be reconstituted. This is carried out by introducing the first chimeric gene and the second chimeric gene into the host cell. The host cell is subjected to conditions under which the first hybrid protein and the second hybrid protein are expressed in sufficient quantity for the function of the amino acid sequence to be reconstituted. The cells are then tested to determine whether the expression of the function of the amino acid sequence has been reconstituted to a degree greater than in the absence of the interaction of the test substances, e.g. proteins. This generalised method can be made more specific for a preferred method of the present invention in which the detectable function is the transcription of a detectable reporter gene. In this method, the first domain of the amino acid sequence includes a DNA-binding domain that recognises a binding site on the detectable reporter gene, and the second domain of the amino acid sequence includes a transcriptional activation domain. In a particularly preferred embodiment of the present invention, the DNA-binding domain and the transcriptional activation domain are from different transcriptional activators. The present invention also relates to a method of preparing a MIF protein comprising: (i) providing a source containing the MIF protein, (ii) contacting the source containing the MIF protein with a source containing the Jabl under conditions allowing for both the (iii) binding of MIF and Jabl and the (iv) separation of MIF from Jabl. The method for purifying MIF from a source for example comprises : a) concentrating the source of MIF; b) absorbing the MIF onto a Jabl-chromatographic support ; c) washing the absorbed MIF with at least one buffer; d) selectively eluting the washed MIF, and e) recovering the MIF from the eluate. Additionally, the method for purifying could be used for: (i) purifying recombinant MIF from bacteria, (ii) purifying native MIF from tissue, (iii) purifying MIF-like homologues such as certain tautomerases , (iv) purifying "native" MIF without harsh treatment whereby Jabl is used as a soft capter molecule . This technique makes use of the fact that MIF and Jabl interact in a specific way. This affinity chromatography relies on the interaction of the MIF protein with an immobilised ligand (e.g. Jabl). The ligand of the invention can be specific for the particular protein of interest, in which case the ligand is a substrate, substrate analogue, inhibitor or antibody which reacts with MIF. In order to isolate MIF from a source such as a cell extract, a sample of the cell extract is for instance placed on a column composed of Jabl-functionalised or coated polymers, and the column is washed repeatedly with buffer. The only proteins that are retained on the column are those with a high affinity to the Jabl anchored to the polymer; other proteins are simply washed out . To elute MIF fixed on the affinity chromatography support of the present invention, a buffer solution containing, at a sufficient concentration, salts and/or known chaotropic agents, such as magnesium chloride or a carbonate buffer may be employed, e.g. since the affinity and specificity between MIF and Jabl is very high, MIF or Jabl can isolated and purified from a cell extract . This chromatography improves the existing method of preparing MIF and it provides a method for preparing Jabl . The polymers used as supports for Jabl can themselves be fixed on a porous mineral support comprising, for example, a metallic oxide such as silica, alumina, magnesia, etc., or natural or synthetic derivatives of these oxide such as glasses, silicates, borosilicates, kaolin etc. The said polymers can be fixed on the porous mineral support by impregnation, the polymer coating then being, if necessary, stabilised by crosslinking in accordance with known methods. The crosslinking agent is, for example, a dicarbonyl compound, a halohydrin, a diepoxide, etc. The polymer supports can also be fixed on mineral supports by means of an intermediate bifunctional coupling agent. The desialyled proteins can also be fixed on the polymeric support by means of an appropriate bifunctional coupling agent, in accordance with known methods. The coupling agents are, for example, bifunctional derivatives such as cyanogen bromide, dialdehydes, diepoxides, etc. The proteins can also be directly fixed on the porous mineral support. For example, in the case of a silica support, an aminoalkyl- silane derivative of silica, is prepared and the desialyled protein is fixed on the aminoalkylsilane using a bifunctional agent such as glutaraldehyde; see for example P. J. Robinson et al, Biochem. Biophys. Acta, 242, 659-661 (1971). The desialyled proteins can also be fixed on porous mineral supports in accordance with the method described in French patent application 77.28163 (publication No. 2.403.098). This process comprises coating a porous mineral support with a polymer capable of undergoing a cleavage reaction oxidising the glycol groups using oxidising agents such as periodates . A polycarbonyl coating is obtained and the ligand, for example, the desialyled glycoprotein, can then be fixed on the carbonyl groups formed. If desired, the imine group formed can be reduced to the amine . Thus, the present invention relates to a method of preparing the Jabl protein comprising: a) providing a source containing the Jabl protein, b) contacting the source containing the Jabl protein with the source containing the MIF protein under conditions following the binding of Jabl and MIF and separating Jabl, the isolated peptides, proteins or fragments can be purified by biochemical methods including, for example, affinity chromatography. Affinity matrices which can be used for MIF or Jabl (e.g. human MIF peptides) isolation can be anti-MIF monoclonal or polyclonal antibodies prepared against the amino acid sequence coding MIF or Jabl, or fragments thereof such as synthetic peptides, recombinant fragments or the like. Alternatively, cognate binding domains or polypeptides as well as other compounds known in the art which specifically bind to MIF can similarly be used as affinity matrices to isolate substantially proteins or antibodies (e.g. pure human MIF proteins, semi-pure mice Jabl polypeptides or antibodies which interact with the MIF-Jabl domain) of the invention. The chromatography provides an isolating method for yet unknown Jabl homologues -such as proteins of the M0V34 family or proteins with a MPN domain like Padl- by binding homologous domains to MIF. In a preferred embodiment of the present invention, the sources containing MIF and/or Jabl are cells including bacteria or yeast or recombinantly pre- pared cells, tissues, cell cultures, cell culture supernatants, cell extracts, protein preparations, isolated MIF or Jabl. In a particularly preferred embodiment of the present invention, the source containing the MIF protein is pre-treated, in particular disrupted, prior to contacting MIF and Jabl, if necessary, for instance, cells used as a source may be sonificated, chemically or enzymatically lysed or subjected to pulsed or constant electrical fields. The present invention also relates to a, preferably isolated and purified, complex protein comprising all or part of the MIF protein in not covalently bonded association with all or part of the Jabl protein. The complex of MIF and Jabl relates to naturally occurring or wildtype complex as well as to any modification, mutants or derivatives such as recombinantly produced complexes containing amino acid modifications, such as inversion, deletions, insertions, substitutions, additions, denatura- tions, oxidations of each of the two components of the complex, i.e. of either MIF or Jabl or both etc .. Thus, the present invention also relates to a, preferably isolated and purified fusion protein comprising all or part of the MIF protein covalently bonded in conjunction with all or part of Jab protein. The fusion protein relates to naturally occurring or wildtype fusion proteins as well as to any modification, mutants or derivatives such as recombinantly produced fusion proteins contain- ing amino acid modifications, such as inversions, deletions, insertions, substitutions, additions, denaturations , oxidations of each of the two components of the complex, i.e. of either MIF or Jabl or both etc .. The present invention also relates to a purified and isolated nucleic acid sequence encoding the fusion protein according to the above, or the complementary strand thereof. The term nucleic acid sequence relates to a natural or synthetic polymer of DNA or RNA which may be single or double stranded, alternately containing a synthetic, non-natural or altered nucleotide base capable of incorporation into DNA or RNA polymers. The nucleic acid molecule may be cDNA, genomic DNA, or RNA, for instance mRNA. The present invention also relates to a vector comprising the nucleic acid sequence according to the above, in particular to a bacterial vector, such as a plasmid, a liposome, a bacteriophage, a retrovi- rus or a virus . Furthermore, the present invention relates to host cells transformed with a vector of the present invention, in particular procaryotic or eucaryotic cells. The present invention also relates to cell cultures, tissues, etc. comprising a cell containing a plasmid according to the above . The present invention also relates to an antibody or fragment thereof which is specifically reactive with the complex of MIF and Jabl or the fusion pro- tein of MIF and Jabl or the interacting domain of MIF and Jabl. These antibodies may be used to screen expression libraries to identify clones which produce the complexes of the present invention and also for therapeutic purposes. As used herein, the term "relates to an antibody" relates to detection, activation or inhibition of molecular and cellular pathways induced by the interaction of Jabl and MIF. The term "antibody" relates to bivalent and monovalent molecular entities that have the property of interaction with a complex of MIF and Jabl. As used herein, "antibody" refers to a protein consisting of one or more polypeptides substantially encoded by immunoglobulin genes or fragments of immunoglobulin genes. Light chains are classified as either kappa or lambda. Heavy chains are classified as gamma, mu, alpha, delta, or epsilon, which in turn define the immunoglobulin classes, IgG, IgM, IgA, IgD and IgE, respectively (for details see definition of the terms) . The phrase "specifically binds to" , when referring to an antibody, refers to a recognition and binding reaction which is determinative of the presence of the domain in question in the presence of a heterogeneous population of proteins and other biologies. Thus, under designated immunoassay conditions, the specified antibodies bind to the particular domain and do not bind in a significant amount to other proteins present in the sample. Specific binding to the domain under such conditions may require an antibody that is selected for its specificity for a MIF-Jab-domain. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with the MIF-Jabl-domain. For exam- pie, solid phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with the domain. The immunoassays which can be used include, but are not limited to, competitive and non-competitive assay systems using techniques such as Western-Blots, radioimmunoas- says, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immuno- diffusion assays, agglutination assays, complement- fixation assays, immunoradiometric assays, fluorescent immunoassays and protein A immunoassays, to name but a few. Antibodies of the invention specifically bind to one or more epitopes on a domain which is involved in the interaction of MIF and Jabl. Epitope refers to the region of a MIF-Jabl- complex or of the MIF-Jabl interacting domain or of the MIF-Jabl fusion protein bound by an antibody, wherein the binding prevents association of a second antibody to an MIF-Jabl-complex, or wherein the antibody prevents binding of other proteins (upstream kinases, c-Jun, JNK, SRC-1, LFA-1, PR, GR, etc. ) . In an embodiment of the invention, the antibodies are polyclonal antibodies, monoclonal antibodies and fragments thereof. Antibody fragments encompass those fragments which interact with an MIF- Jabl-complex. Also encompassed are humanised antibodies, typically produced by recombinant methods, wherein human sequences comprise part or all of an antibody which interacts with a MIF-Jabl-complex. Examples of humanised antibodies include chimeric or CDR-grafted antibodies. Also included are fully human antibodies of the MIF-Jabl-complex produced in genetically altered mice. Antibodies of the invention may also have a detectable label attached thereto. Such a label may be a fluorescent (e.g. fluorescein isothiocyanate, FITC) , enzymatic (e.g. horse radish oxidase) , affinity (e.g. biotin), or isotopic label (e.g. 125 I) . Also encompassed by the invention are hybridoma cell lines producing a monoclonal antibody which interacts with a MIF-Jabl-complex. The antibodies of the present invention are useful in diagnosing MIF related diseases. Antibodies may be used as part of a diagnostic kit to detect the presence of the interaction of MIF and Jabl in a biological sample. The biological samples include tissues, specimens and intact cells or extracts thereof. Such kits employ antibodies having an attached label to allow for detection. The antibodies are useful for identifying normal domains of the interaction of MIF and Jabl; the antibodies of the invention are also useful for diagnosing and therapy. The present invention also relates to a kit comprising nucleic acid sequence which encodes the fusion protein of the invention, the vector comprising said nucleic acid sequence, the host cell comprising said vector, the DNA sequence encoding MIF and/or Jabl, the complex or fusion molecule comprising MIF and/or Jabl and the antibodies of the invention. In the context of the invention, the MIF-Jabl complex can be contained in liposomes with a pure lipid or biological membrane. The DNA which encodes MIF-Jab complex can be used as adjuvant or as a substance for immunisation. The liposomes or the adjuvant are useful for diagnosis and therapy of MIF- and/or Jabl-related diseases. The method of the present invention as described above may be practised using a kit for detecting the interaction between a MIF and a Jabl . The kit includes a container, two vectors and a host cell. The first vector contains a promoter and may include a transcription termination signal functionally associated with the first chimeric gene in order to direct the transcription of the first chimeric gene. The first chimeric gene includes a DNA sequence that encodes a DNA-binding domain and unique restriction sites for inserting a DNA sequence encoding a protein with an activity of MIF or a protein fragment of the activity of MIF in such a manner that the MIF is expressed as part of a hybrid protein with a DNA-binding domain. The first vector also includes a means for replicating itself in the host cell and in bacteria. Also included on the first vector is a first marker gene, the expression of which in the host cell permits selection of cells containing the first marker gene from cells that do not contain the first marker gene; the first vector is preferably a plasmid. All the above identified methods to detect interaction between MIF and Jabl, in particular to screen for a drug, are carried out under conventional conditions, binding assays for instance in aqueous medium under conditions suitable to detect binding of MIF to Jabl. The kit also includes a second vector which contains a second chimeric gene. The second chimeric gene also includes a promoter and a transcription termination signal to direct transcription. The second chimeric gene also includes a DNA sequence, certain coded transcriptional activation domains and a unique restriction site to insert a DNA sequence encoding the protein or protein fragment with the activity of Jabl into the vector in such a manner that the Jabl or the protein or protein fragment with the Jabl activity is capable of being expressed as a part of a hybrid protein with a transcriptional activation domain. The DNA binding domain of the first hybrid protein and the transcriptional activation domain of the second hybrid protein are preferably derived from transcriptional activators having separate DNA binding and transcriptional activation domains. The separate DNA binding and transcriptional activation domains are also known to be found in the yeast GAL4 protein and are also known to be found in the yeast GCN4 and ADR1 proteins. Many other proteins involved in transcription also have separable binding and transcriptional activation domains which render them useful for the present invention. In another embodiment, the DNA-binding domain in the transcriptional activation domain may be from different transcriptional activators. The second hybrid protein may be encoded on the library of plasmids that contain genomic, cDNA or synthetically generated DNA sequences fused to the DNA sequence encoding the transcriptional activation domain. The second vector further includes a means for replicating itself in the host cell and in bacteria. The second vector also includes a second marker gene, expression of which in the host cell permits selection of cells containing the second marker gene from cells that do not contain the second marker gene . The kit includes a host cell which contains the detectable reporter gene having a binding site for a DNA- binding domain of the first hybrid protein. The binding site is positioned so that the reporter gene expresses a detectable protein when the detectable reporter gene is activated by the transcriptional activation domain encoded by the second vector. Activation of the detectable gene is possible if the transcriptional activation domain is in sufficient proximity to the reporter gene. The host cell itself is incapable of expressing a protein having a function of the first marker gene, the second marker gene, the DNA-binding domain or the transcriptional activation domain. Accordingly, through use of the kit, the interaction of MIF and Jabl in the host cell causes a measurably greater expression of the reporter gene than is the case when the DNA-binding domains in the transcriptional activation domain are present, in the absence of interaction between the MIF and the Jabl protein. The reporter gene may encode an enzyme or other products that can be readily measured. The cells containing the two hybrid proteins are incubated in a appropriate medium and the culture is monitored for the measurable activity. A positive test for this activity is an indication that the MIF and the Jabl protein have interacted. Such interaction brings their respective DNA-binding and transcriptional activation domains into suffi- ciently close proximity to cause transcription of the marker gene . The present invention also relates to protein array kits for detecting the influence of candidate drugs on the interaction between MIF and Jabl. One kit comprises in a container a biochip, wherein MIF is directly immobilised on a solid support, a biochip, wherein Jabl is directly immobilised on a solid support, a MIF protein or peptide in lyophilised form, a Jabl protein or peptide in lyophilised form and a buffer system. Another kit comprises two biochips, wherein each of MIF and Jabl is immobilised as a GST-protein on a GSH-support, lyophilised MIF, lyophilised Jabl and a buffer system. Another kit comprises two biochips, wherein each of MIF and Jabl is immobilised as a biotin-protein on a Streptavidin-support , lyophilised MIF, lyophilised Jabl and a buffer system. Another kit comprises two biochips, wherein each of MIF and Jabl is immobilised as a MBP-protein on a malate-support, lyophilised MIF, lyophilised Jabl and a buffer system. The different kits for screening potential drugs are used as follows. The lyophilised MIF protein or peptide is dissolved in the buffer and is then brought into contact with the biochip comprising the immobilised Jabl in the presence or absence of a potential drug. For comparison the lyophilised Jabl peptide or protein is also dissolved in the buffer und brought into contact with the biochip comprising the immobilised MIF in the presence or absence of a potential drug. Then the above described methods to detect the interaction between MIF and Jabl, in particular fluorescence or MALDI-MS methods are conducted under conventional conditions. The present invention also relates to a pharmaceutical or diagnostic composition comprising the nucleic acid sequence of the invention, the vector comprising this nucleic acid sequence, the host cell which comprises the vector of the invention, the DNA sequence encoding Jabl and/or MIF, the antibodies of the invention and/or the complex or fusion molecules which comprise MIF and Jabl, optionally in conjunction with a pharmaceutically acceptable carrier and/or further additives such as flavouring agents, binders, sweeteners, fillers, bulking agents, pharmaceutically acceptable salts, anorganic or organic acids, preservatives, emulga- tors etc. The present invention also relates to the use of Jabl or a Jabl coding nucleotide sequence to modulate the activity of MIF, in particular for treatment of MIF-related diseases. Thus, the present invention also relates to the use of Jabl or a Jabl coding nucleotide sequence for preparing a medicament, drug or therapeutic agent for the treatment of MIF-related diseases. Furthermore, the present invention relates to the use of Jabl or a Jabl coding nucleotide sequence for the detection of MIF-related diseases. The present invention relates to the use of the complex protein and/or the fusion protein for pre- paring a drug for the diagnosis and/or treatment of MIF-related diseases. Furthermore, the present invention relates to the use of the complex protein and/or the fusion protein for the diagnosis and/or treatment of MIF- related diseases. The present invention also relates to the use of the antibodies or a fragment thereof recognising specifically the complex and/or the fusion protein comprising all or part of MIF in association with all or part of Jabl or an antibody recognising Jabl or a fragment thereof for preparing a drug for the diagnosis and/or treatment of MIF-related diseases. The present invention also relates to the use of the antibody of the invention or an antibody to Jabl or a fragment thereof for the diagnosis and/or treatment of MIF-related diseases. Furthermore, the present invention relates to a drug comprising Jabl or a part thereof for a Jabl coding nucleotide sequence or an antibody specifically recognising Jabl in a pharmaceutically effective amount. The present invention relates to the use of the MIF or a MIF coding nucleotide sequence to modulate the activity of Jabl, in particular for treatment of Jabl-related diseases. Jabl-related diseases refers to inflammatory and/or anti-inflammatory effects, the regulation of immunomodulated pathways, septic shock, physiological stress, diseases in connection with cytokine activity, cytokine depend- ent signalling pathways, cell cycle dependent diseases, skin diseases such as UV-induced skin disorders, abnormal cell growth diseases and cancer and inflammatory processes. The present invention relates also to the use of MIF or the MIF coding nucleotide sequence for preparing a drug for the diagnosis and/or treatment of Jabl-related diseases. Thus, the present invention also relates to a process for modifying Jabl activity in vivo or in vitro, in particular for diagnosing or treating a Jabl related disease, whereby MIF, part of MIF, a MIF antibody, a MIF nucleotide sequence, such as a DNA or mRNA, possibly cloned for instance in sense or antisense orientation to appropriate regulatory elements in a vector is used to modulate and/or regulate Jabl activity and/or expression thereof by e.g. modifying transcription, degradation of Kip, binding of c-Jun and/or modifying the cell cycle etc . Furthermore, the present invention relates to the use of MIF or the MIF coding nucleotide sequence for the diagnosis and/or treatment of Jabl-related diseases . Thus, the present invention relates to the use of the complex protein comprising all or part of MIF in association with all or part of Jabl, optionally in association with Kip and/or c-Jun or JunD and/or JNK and/or SRC-1 and/or LFA-1 and/or PR and/or GR, and/or the fusion protein comprising all or part of MIF in conjunction with all or part of Jabl, optionally in conjunction with Kip and/or c-Jun or JunD for preparing a drug for diagnosis and/or treatment of Jabl-related diseases. The present invention relates also to the use of the complex protein of the invention and/or the fusion protein of the invention for diagnosis and/or treatment of Jabl-related diseases. The present invention relates to use of the antibody or a fragment thereof recognising specifically the complex or the fusion protein of the present invention or an antibody to MIF or a fragment thereof for preparing a drug for the diagnosis and/or treatment of Jabl-related diseases. The present invention also relates to the use of the antibody or a fragment thereof recognising specifically the complex and/or the fusion protein of the present invention or an antibody to MIF or a fragment thereof for the diagnosis and/or the treatment of Jabl-related diseases. Furthermore, the present invention relates to a drug comprising MIF or a part thereof or a MIF coding nucleotide sequence or an antibody specifically recognising MIF in a pharmaceutically effective amount . Further preferred embodiments are exemplified in the subclaims. Figure 1 shows interaction of MIF with Jabl. Figure 2 shows that MIF specifically interacts with Jabl. Figure 3 shows that MIF inhibits stimulated AP-1 activity. Figure 4 shows that MIF inhibits potentiation of AP-1 reporter gene activity (collagenase 5xl2-o-tetradecanol phorbol acetate response element (TRE) promoter) by Jabl and UV stress. Figure 5 shows Jabl enhances JNK activity and phospho-c-Jun levels and MIF inhibits these effects. Figure 6 shows modulation of JNK by Jabl and MIF. Figure 7 shows that MIF stabilises p27 ipl protein and inhibits fibroblast growth in a Jabl- dependent manner. Figure 8 shows the mechanism of p27 Kιpl induction by MIF. Figure 9 shows the characterisation of the binding site between MIF and Jabl. Figure 10 shows the effect of MIF on growth arrest of fibroblasts. SEQ ID No. 1 depicts the amino acid sequence of MIF (50 - 65) . SEQ ID No. 2 depicts the amino acid sequence of Ser 57 Ser 60 MIF (50 - 65) . The following examples are offered to more fully illustrate the invention, but are not construed as limiting the scope thereof. Example 1 : Detecting interaction of MIF with Jabl using the two hybrid system. Materials and methods used throughout the examples Recombinant proteins, fusion constructs, and antibodies Recombinant human MIF was purified from E. coli as described in Kleemann et al, Eur. J. Biochem 261, 753 (1999). For [35S] -radiolabelling, human MIF was expressed in E. coli BL21(DE3) grown in standard minimal medium supplemented with PRO-MIX (Amersham) and purified as described for rMIF in Bernhagen, Biochemistry 33, 14144 (1994). The complete coding sequence of Jabl was obtained by RT- PCR from Jurkat cells and confirmed by bidirectional sequencing. The Jabl cDNA was cloned into the pCl-neo vector (Promega) for expression in the in vitro translation and transfection experiments. TNF was from R&D Systems. EGFP fusion proteins: EGFP was C-terminally fused to MIF using the pN3- EGFP vector (Clontech) . P33-EGFP as a mitochon- drial marker has been described. PKCμ (KD) -EGFP shows cytosolic localisation, and was used as the respective control. Rabbit polyclonal anti-rMIF antibody was obtained as described in Bernhagen et al., Nature 365, 756 (1993). All other antibodies were from Santa Cruz Biotechnology. In vitro transcription/translation reaction Coupled in vitro transcription/translation reactions were performed with the TNT T7 Quick reticu- locyte-lysate system in combination with the Transcend non-radioactive translation detection system (Promega) . Expression of Jabl and c-Jun was achieved using plasmids pCl-neo-Jabl (see above) and pBAT-c-Jun. Expression efficiency of biotin- labelled Jabl and c-Jun was confirmed by immunoblotting using anti-Jabl or anti-c-Jun anti- body, respectively, or by staining with strepta- vidin/horse radish peroxidase conjugate (S-HRP) . Protein-protein interaction Immobilisation of rMIF was performed on Affigel 10 agarose (BIO-RAD) at pH 8.5 following the manufacturer's recommendations. Control beads were blocked with L-glycine, pH 8, and bovine serum albumin (BSA) . Binding of Jabl to beads was analysed in lysates from 293T cells that had been transiently transfected with pCl-neo-Jabl for 48 h (efficiency > 80%) . Cell lysis (30 min. on ice) was done in 25 mM HEPES, pH 7.7, 0.4 NaCl, 1.5 mM MgCl 2 , 2 mM EDTA, 0.5% Triton X-100, 3 mM DTT, and 1 x proteinase inhibitor cocktail (PI) (Roche Diagnostics) . Binding and washes were performed in the same buffer, except that NaCl was diluted to 0.1 M. For binding of soluble rMIF to Jabl, TNT reticulo- cyte lysates were supplemented with 1 μM rMIF of BSA, biotin-labelled Jabl or c-Jun expressed by in vitro transcription/translation, reactions diluted sixfold in phosphate-buffered saline (PBS) containing PI, and reactions rotated at 4° C for 3 h. Antibody was added, reactions incubated for 1 h, and immunoprecipitates bound to protein A-Sepharose (Amersham-Pharmacia) (1 h, 4° C) , washed in PBS, and then 50 mM Tris-HCl, pH 8.0, 170 mM NaCl, 0.5% NP- 40, 50 mM NaF. Coimmunoprecipitated biotinylated proteins were detected by immunoblotting and S-HRP staining. For co-precipitation of biotinylated MIF-EGFP with Jabl, strepavidin-conjugated magnetic beads (Dynal) were used, complexes washed as above, and Jabl detected with anti-Jabl antibody following immunoblotting. For binding of soluble rMIF to in vitro-synthesised Jabl, TNT lysates were depleted of endogenous MIF (estimated at lOnM) by incubation of lysates in ELISA plates coated with anti-MIF antibodies (lOOμg/well) for 1 h at 4°C. Lysates were supplemented with 1 μM rMIF, control buffer, or bovine serum albumin (BSA) , and biotin-labelled Jabl or c- Jun expressed. Reactions were diluted 6-fold in phosphate-buffered saline (PBS) containing protein- ase inhibitor cocktail (PI) (Roche) , and rotated at 4°C for 3 h. Complexes were immunoprecipitated by antibody/protein A-Sepharose (Amersham-Pharmacia) (1 h each, 4°C) , washed in PBS, and then 50 mM Tris-HCI, pH 8.0, 170 mM NaCl, 0.5% NP-40, 50 mM NaF . Coimmunoprecipitated biotinylated proteins were detected by immunoblotting and S-HRP staining. Interaction of endogenous MIF with endogenous Jabl was analysed in lysates of untreated 293T cells. MIF/Jabl complexes were precipitated with anti-Jabl in comparison to control antibody or protein A- Sepharose alone and immunoblots analysed with anti- MIF antibody. Tissue culture and transient transfections Cell lines were cultured according to the recommended standard procedures. All transient trans- fections were performed using Superfect (Qiagen) . For coincubations with rMIF, MIF was added 2 h after addition of plasmids. Transfections of serum- starved NIH3T3 cells were performed as reported (Tomoda et al . 1999). Raw cells expressing reduced amounts of endogenous MIF protein were obtained by transfecting cells with the pBK/antisense MIF expression vector (Waeber et al . , 1997). Control cells were transfected with an empty pBK plasmid. Stably transfected clones were isolated. One clone, ΔAS 2.23, expressing <50% of MIF content of control cells, was used. Raw or HeLa cells were incubated with [35S]rMIF, FLUOS-MIF, biotin-MIF (1 μM each) , or labelling reagents alone for 1 h, cells washed in ice-cold PBS and 50 mM glycine, 150 mM NaCl, pH 3, and prepared for liquid scintillation counting, fluorescent microscopy, or confocal microscopy by standard procedures. For [35S]rMIF experiments, cells were subjected to subcellular fractionation by differential centrifugation and cytosolic fractions analysed by PD10 gel filtration. For colocalisation studies, HeLa cells were transfected (1 μg pMIF- EGFP) and cells incubated for 24 h. Cells were washed, fixed permeabilised with 0.05% Tween-20, and blocked with 5% goat serum. For Jabl staining, anti-Jabl antibody and Alexa-546 staining was used. Samples were analysed with a confocal laser scanning microscope (Leica) using filters for Alexa- 546, GFP, and FLUOS emissions. Activity assays AP-1 reporter gene activity was measured as reported (Johannes et al . , 1998). 0.15 μg of pCl- neo-Jabl or empty plasmid and 0.05 μg of each the Tk-LUC-5xl2-o-tetradecanol phorbol acetate (TRE) (Angel et al . , 1987), R15-RSV-LacZ reporter constructs, and the pEGFP plasmid were used. Incubations with rMIF were performed for 18 h. NFicB reporter gene activity measurements in 293T cells were performed as described (Johannes et al . , 1998) , with rMIF added for 40 h. The NFKB assay in Raw cells was performed as described (Roger et al . , 1998) . JNK assays were performed as described (Berberich et al . , 1996), with rMIF added for 48 h. p27 ιpl induction experiments and proliferation studies were performed following a published procedure (Tomoda et al . , 1999) . For pulse-chase labelling of p27 Kιpl , a previous method (Tomoda et al . , 1999) was adapted, with synchronised fibroblasts plated at 7 x 10 5 cells/well, and 1 μM rMIF added at plating, the pulse, and for the chase period. Results : Interaction of MIF with Jabl In order to test the possibility that MIF has direct intracellular functions by interacting with intracellular proteins, the two-hybrid screen was used. The entire coding region of human MIF was fused in-frame to the GAL4 DNA-binding domain using the pAS2-l vector. With the resulting bait plasmid pMIF-BD, a human fetal brain library was screened by the yeast two-hybrid method essentially as described by the manufacturer (Clontech) . Although MIF oligomerises, autoactivation by MIF was not detected. Following selection on Trp-Leu-His-medium and testing the resultant clones for β- galactosidase activity, three positive GAL4 DNA- activation domain fusion proteins were obtained. The results of the β-galactosidase assay in liquid media are in Miller units and are the means ± SD of 7 measurements from independent clones . As MIF is abundantly expressed in the brain and in lymphocytes, a human whole brain and a lymphocyte cDNA library were employed and full-length human MIF cDNA was used as a bait. From 3.5 x 10 6 and 3.0 x 10 6 transfectants, respectively, a total of 4 types of clones that interacted specifically when tested for nutritional selection and β- galactosidase activity was identified. One such clone contained a cDNA insert, with almost the entire coding sequence (corresponding to amino acids 20-335) of human p38 Jabl . (identity: > 99% to the corresponding p38 Jabl sequence) . The entire coding sequence of 2 other clones was 100% identical to the human MIF cDNA sequence, confirming that MIF self-associates into oligomeres. It is concluded that MIF specifically binds to Jabl in the yeast two-hybrid assay. Figure 1 shows interaction of MIF with Jabl. a, MIF specifically binds to Jabl in the yeast two-hybrid assay. Growth of transformants coexpressing MIF and Jabl on selective medium. MIF-BD corresponds to the Gal4-BD/MIF fusion construct; Jabl-AD and MIF-AD represent the clones obtained from the screening. Lamin-BD, Gal4-BD, and Gal4-AD were negative and p53-BD and SV40-AD positive controls. Upper panel, transformation of BD clones first; lower panel, transformation of AD clones first. Leu+ Trp+ trans- formants were streaked on media lacking leucine and tryptophan (+ His) or leucine, tryptophan, and his- tidine (- His) . When quantitated by a liquid media assay, beta-galactosidase activity of the Jabl- AD/MIF-BD sample was found to have 2.1 ± 0.2 beta- galactosidase (β-Gal) units as compared to 0.1 + 0.1 units for GAL4-AD/GAL4-BD, 0.1 ± 0.04 units for GAL4-AD/MIF-BD, and 0.3 ± 0.1 units for JAB1- AD/GAL4-BD. The SV40-AD/p53-BD positive control had 99 ±25 units. The results of the beta-galactosidase assay in liquid media are in Miller units and are the mean SD of 7 measurements from independent clones, b, Immobilised MIF specifically interacts with Jabl. MIF immobilised on streptavidin beads was incubated with Jabl overexpressed in 293T cells, complexes isolated by pull-down, and bound Jabl detected by immunoblotting with anti-Jabl antibody/HRP-ECL staining, c, Interaction of endogenous MIF with endogenous Jabl in vivo. Metabolic labelling of MIF-positive versus MIF-negative cells and pull-down of endogenous MIF/Jabl complexes by anti-MIFantibody. Left panel, MIF-positive NIH 3T3 fibroblasts versus MIF-negative Kym-1 cells were labelled with [35S] cysteine/methionine, MIF- containing complexes immunoprecipitated with anti- MIF versus non- immune antibody, and bound radioactive proteins electrophoresed. 14 C-radiolabelled molecular weight marker was co-electrophoresed. Fibroblasts (1 x 10 6 cell equivalents) were MIF- positive by Western blotting (scored 3 on a scale of 0-3) and were determined to contain > 300 fg MIF/cell by ELISA. Kym-1 cells were MIF-negative by Western blotting (score of 0) and contained 7 + 5 fg MIF/cell (mean ± SD; n = 3) as measured by ELISA. Right panel, anti-Jabl and anti-MIF control Western blots. Anti-Jabl Western blot in the lower panel demonstrates that Kym-1 and NIH 3T3 cells contain approximately equal concentrations of endogenous Jabl. For this Western analysis, 5 x 10 5 cell equivalents were electrophoresed for each cell type. Staining was performed with anti-Jabl anti- body/HRP-ECL chemiluminescence . Example 2 : Detecting interaction of MIF with Jab using co- precipitation The specificity of the interaction between MIF and p38 abl was probed by in vitro co-precipitation experiments. Purified recombinant human MIF (rMIF) was immobilised on agarose beads, and binding to full length p38 Jabl that was cloned from Jurkat T cells and overexpressed in 293 human embryonal kidney cell was assessed. P38 Jabl strongly bound to the MIF beads, whereas only non-specific background binding was observed to non-functionalised control beads. Furthermore, soluble rMIF could specifically bind to in vitro-translated biotin-labelled p38 Jabl , whereas biotin-labelled c-Jun was not co- precipitated by MIF. Reversely, biotin-labelled MIF-enhanced green fluorescent protein (MIF-EGFP) fusion protein bound to p38 Jabl . Significant portions of p38 Ja l are found in the nucleus and cytosol, suggesting that interaction with MIF would occur in one of these compartments. Staining of endogenous MIF with anti-MIF antibody and Cy-2 and transient transfection of a MIF-EGFP fusion protein in HeLa and COS-1 cells and microscopic comparison of the subcellular localisation with other EGFP-linked marker proteins revealed that both endogenous MIF and overexpressed MIF fusion protein predominantly located to the cytosol . As circulating extracellular MIF is critical for the numerous immunological functions of MIF, it was also tested whether extracellular MIF may be targeted to the cytosol. Exogenously added [35S]rMIF, in addition to being recoverable from the lysosome fraction, was targeted to the cytosol in significant concentrations and was stable there for several hours, indicating that transcellularly acting MIF could interact with p38 Jabl following uptake into target cells. Specific complex formation between MIF and Jabl in vi tro was also observed when both proteins were expressed in the in vi tro translation system. It is demonstrated that complexes of biotin-labelled MIF- enhanced green fluorescent protein (MIF-EGFP) fusion protein and non-biotinylated Jabl were specifically precipitated. Furthermore, biotinylated rMIF, when added to Raw 264.7 macrophages or HeLa cells, bound to endogenous Jabl in vivo . This latter finding also demonstrates that MIF added exogenously to cells can bind to endogenous intracellular Jabl following endocytosis. Finally, in vivo interaction of the endogenous partners was probed. Endogenous Jabl/MIF complexes were precipitated from untreated 293T cells. Specific coprecipitation of MIF was detected by anti- MIF Western blot when anti-Jabl antibody but not control antibody was sued for coprecipitation. Thus, MIF specifically binds to p38 Jabl both in vivo and in vitro. Figure 2 shows that MIF specifically interacts with Jabl. a, Interaction in vi tro . Complexes of rMIF and biotin-Jabl expressed in TNT lysates were precipitated by MIF-specific antibody, and biotinylated proteins detected by Western blotting (left panel). Right panel, expression control, b, Interaction of immobilised MIF with Jabl. Streptavidin bead-immobilised TNT-translated biotin-MIF-EGFP or unlabelled control was incubated with TNT- translated Jabl, complexes isolated, and Jabl detected by immunoblotting. c, Interaction of MIF and Jabl in vivo . Endogenous Jabl/MIF complexes were immunoprecipitated from 293T cell lysates with anti-Jabl antibody and MIF detected by immunoblotting. Precipitation with anti-TNF antibody or beads alone served as controls. Example 3 : Detecting interaction of MIF with Jab using modulation of AP-1-dependent reporter gene activity. Transcriptional coactivator function of Jabl is due to enhancement of AP-1 transcriptional activity. It was tested whether MIF, by binding to Jabl, could modulate this activity. AP-1 dependent reporter gene activity in 293T cells transiently expressing the collagenase TRE luciferase reporter was measured. The effects of MIF were assessed by measuring AP-1- dependent reporter gene activity in transfected 293T cells using the 5 x TRE- luciferase reporter. Recombinant MIF, in a concentration-dependent manner, fully reversed TNF-α-induced AP-1-dependent reporter gene activity and, at a concentration of 1 μM, fully inhibited potentiation of AP-1 reporter gene activity induced by p38 Jabl which had been transiently cotransfected into cells as full-length cDNA together with the addition of rMIF. Inhibition of AP-1 activity by MIF was not a secondary effect of MIF-mediated altered cell growth. Significant potentiation by p38 abl (2-fold) was observed in the absence of transfected c-Jun, indicating that endogenous c-Jun levels were sufficient for potentiation by p38 Jabl to occur. Inhibition by MIF was already significant at 1 pM (-30%) and was complete when 10 nM - 1 μM rMIF were applied. Figure 3 shows that MIF inhibits stimulated AP-1 activity. a, MIF inhibits Jabl-mediated activation of AP-1 reporter gene activity in 293T cells. Transfections with pCI-neo-Jabl or control vector are compared with or without (-) rMIF. b, MIF inhibits TNF-induced AP-1 activity. Same as a, but with TNF instead of Jabl induction. Stimulation by PMA was a control . Data represent means ± SD of four determinations and are representative of three experiments, c, MIF does not inhibit stimulated NFicB reporter gene activity. TNF-induced NFicB from antisense MIF macrophages with reduced content of endogenous MIF (+ as-MIF) is compared with activities of control (+ control) and non-transfected (-) cells. The mean ± SD of 3 measurements is given. LUC, relative luciferase activity. Figure 4 shows that MIF inhibits potentiation of AP-1 reporter gene activity (collagenase 5xl2-o- tetradecanol phorbol acetate response element (TRE) promoter) by Jabl and UV stress. 293T cells were transfected with the reporter plasmids and, where indicated, cotransfected with pCl-neo-Jabl or empty control vector and incubated with the indicated concentrations of rMIF or buffer control for 18 h. a, Western blotting control experiment for Figure 3a displaying analysis of Jabl overexpression and control EGFP cotransfection by anti-Jabl and anti- GFP-Western. The co-transfected EGFP construct (pN3-EGFP, Clontech) was added at 0.05 μg per incubation. In addition, EGFP-positive cells were counted at the end of the incubation. Transfection efficiencies judged by this analysis was 45-50% for Figure 3a and 35-45% for Figure 3b. An effect of MIF itself on 293T cell growth under the conditions of the assay was excluded by additional cell counts. Wells after the end of the incubation period contained 2.3-2.5 x 10 5 cells (Figure 3a) and 3.8-4.1 x 10 4 cells (Figure 3b) . Results are expressed as relative luciferase (LUC) activity, b, MIF inhibits UV stress-induced AP-1 transcriptional activity. Same as Figure 3b, but with UV light induction (Stratalinker, 3.6 Joule/cm 2 , 20 min + 90 min) instead of TNF treatment . Data represent the mean ± SD of 4 measurements, c, MIF does not interfere with stimulated NFkappaB activity. Recombinant MIF (rMIF) does not inhibit TNF-induced NFkappaB reporter gene activity in 293T cells. Cells were transfected with the reporter plasmids and incubations with rMIF (40 h) performed at a concentration of 1 μM. TNF was added at a concentration of 10 ng/ml (6 h) . Results are relative luciferase (LUC) activities and represent the mean ± SD of 3 determinations . MIF also inhibits TNF- and UV- stress-induced AP-1 transcriptional activity. Neither exogenously added nor endogenously MIF interferes with NFJCB activity. Recombinant MIF (lμM) has no effect on TNF induced NFxB reporter gene activity in 293T cells. Example 4 : Detecting interaction of MIF with Jabl using elec- tromobility-shift assay (EMSA) . A transcriptional co-activator function by p38 Jabl is due to enhancement of the binding of c-Jun to the AP-1 site. Thus, it was assumed that MIF, by binding to p38 Jabl , could modulate this activity. Such an effect on DNA binding was assessed by performing electromobility-shift assay (EMSA) on nuclear extracts from 293 cells that had been transfected with p38 Jabl and/or c-Jun and that had been incubated in the presence or absence of rMIF, using the 12-o-tetradecanol phorbol acetate response element (TRE) . p38 Jabl promoted binding of c-Jun to the TRE. When MIF was incubated with cells overex- pressing both p38 Jabl and c-Jun, a marked inhibition (2-fold) of the . activatory effect of p38 Jabl on the binding of c-Jun to the AP-1 site was seen. By contrast, when only one or none of the transcriptional factors was overexpressed, MIF exhibited a small activatory effect, but this effect was not seen in EMSA from programmed reticulocyte lysates. EMSA from nuclear extracts of the HeLa Tet-off cell line HtTA, which stably expresses the tetracycline- controlled transactivator system and into which the human MIF cDNA was stably transfected to overexpress the MIF protein 5-6-fold over endogenous MIF following removal of doxycyclin, confirmed that MIF can significantly inhibit AP-1-dependent DNA shifts. The degree of inhibition in this system is probably even more marked, because the band intensity in the doxycyclin-repressed incubation likely represents a DNA shift that is already inhibited by the significant concentrations of endogenous MIF (-100 fg/cell) . Example 5 : MIF and p38 Jabl regulate cell signalling pathways To test whether p38 Jabl and MIF could act to more broadly regulate cell signalling pathways, regulation of AP-1 activity by mechanisms upstream of direct transcriptional control was investigated. It was considered that p38 Jabl may modulate JNK activity. Transient transfections of 293 cells with p38 Jabl revealed that immuno-precipitated kinase activity on GST-c-Jun (1-79) was markedly stimulated by p38 Jabl . Enhancement by p38 Jabl was 2 -3 -fold and was stronger than N-terminal phosphorylation of GST-c-Jun (1-79) following stimulation with standard concentrations of TNF-α. It was investigated whether MIF would also inhibit this p38 Jabl -mediated effect. Recombinant MIF, in a dose-dependent fashion, completely reversed enhancement of JNK activity by p38 Jabl . Thus, recombinant MIF reversed enhancement of JNK-activity by Jabl. 200 nM MIF or more led to complete inhibition. Similarly, TNF-α- induced JNK activity was suppressed to baseline levels following treatment with rMIF. The MIF- p38 Jabl interaction should occur independently of whether MIF is endogenously overexpressed or exoge- nously added to cells. This was verified tested by transient transfection experiments, where TNF-α- or p38 Jabl -induced JNK activity was measured in 293 cells that had been co-tranfected with MIF-EGFP or EGFP alone. Similar to the exogenously added rMIF, the endogenously overexpressed MIF fully suppressed both TNF-α- and p38 Jabl -mediated activation of JNK. Figure 5 shows that Jabl enhances JNK activity and phospho-c-Jun levels and MIF inhibits these effects, a, rMIF inhibits Jabl-mediated enhancement of JNK activity. Left, comparison of phosphorylation of GST-c-Jun (1-79) by JNK immunoprecipitates from 293T cells transfected with pCI-neo-Jabl versus empty vector and treated with rMIF or buffer. Relative activation indicates band intensities. Control, TNF induction. Right, as left but co- transfection of antisense-Jabl plasmid where indicated (control, immunoblots of JNK levels; transfection efficiences: 40 - 50%; variances: ± 10%; induction of JNK by Jabl: 1.6-fold ± SD of 0.08; n = 3) . b, Inhibition by MIF of Jabl-induced phosphorylation of endogenous c-Jun. Incubations as in 4a but immunoblots of phospho-c-Jun analysed. Beta- actin immunoblots served as control. c, As b, but phosphorylation of c-Jun induced by TNF or UV stress . Figure 6 shows modulation of JNK by Jabl and MIF. a, Inhibition of TNF-stimulated JNK activity by rMIF. 293T cells were transfected with FLAG-tagged JNK-coding vector and incubated with TNF (20 ng/ml) and rMIF or buffer control as indicated for 48 h. JNK immunoprecipitates were used to phosphorylate GST-c-Jun (1-79) and relative band intensities (indicated as relative activation) estimated by phosphoimage scanning. Control Western blots were analysed by anti -FLAG-antibody. Variances were generally in the range of ± 10%. b, Enhancement of the binding of JNK to c-Jun beads by Jabl but absence of interference by MIF. Possible effects of Jabl and MIF on the binding avidity of c-Jun to JNK were investigated by analysing the effect of Jabl over- expression and MIF coincubation on the binding of endogenous JNK to GST-c-Jun (1-79) beads in lysates from 293T cells. Transfection of cells with Jabl led to an enhanced binding of JNK to c-Jun beads compared to control-transfected cells. Addition of rMIF did not influence this Jabl effect. 293T cells were transfected with Jabl vector as in Figure 4a of the manuscript and cell lysates incubated with GSH agarose-bound GST-c-Jun (1-79) . Eluted complexes were incubated and precipitated with anti-JNK antibody in the presence or absence of rMIF and bound proteins analysed by anti-JNK (internal control) , anti-GST, and anti-c-Jun Western blotting. Example 6 : To investigate whether MIF could also negatively regulate Jabl action with regard to non-AP-1- related activities, the effect of MIF on the cell cycle inhibitor p27 Kιpl which binds to Jabl and whose degradation is instigated by Jabl was studied. Contrary to Jabl, which suppresses p27 Kιpl levels, MIF, in a dose-dependent manner, induced p27 Kιpl levels, as indicated by immunoblots prepared from lysates of proliferating NIH 3T3 fibroblasts and Jurkat T cells. This induction was Jabl- dependent as p27 Kιpl levels did not rise in response to rMIF when cells were transfected with antisense Jabl construct which almost completely suppressed endogenous Jabl protein. p27 Kιpl induces Gl growth arrest and Jabl can rescue serum-starved fibroblasts from growth arrest . It was found that over- expressed MIF-EGFP or exogenous rMIF, in a concentration-dependent manner, inhibited both Jabl- induced reduction of serum dependence of fibroblasts and growth of proliferating fibroblasts. As MIF did not directly bind to p27 Kιpl , did not stimulate p27 Kιpl mRNA or protein synthesis, and as Jabl promotes the proteasome-dependent degradation of p27 κipl , effects of MIF in the context of p27 κipl degradation were analysed. p27 Kιpl levels, when measured by immunoprecipitation from synchronised, pulse-chase-labelled fibroblasts were higher in the presence of added rMIF. The stabilising effect of MIF on p27 Kιpl levels was not further enhanced by addition of the proteasome inhibitor LLnL. By contrast, enhancement of p27 Kιpl levels by MIF alone was even more pronounced than by LLnL alone . At the same time, addition of MIF slightly increased p27 Kιpl levels in the presence of a protein synthesis blocker. As coimmunoprecipitation studies indicated that MIF partially interfered with p27 κipl /Jabl complex formation, these data show that MIF- mediated effects mirror p27 Kιpl -mediated growth arrest and that this occurs via inhibition of Jabl- dependent degradation of p27 Kιpl . Figure 7 shows that MIF stabilises p27 κipl protein and inhibits fibroblast growth in a Jabl-dependent manner. a, MIF induces p27 Kιpl expression in fibroblasts (p27 Kιpl immunoblots and c-Jun control blots) . b, p27 κipl induction by MIF is Jabl- dependent . Left, As a, but additional transfection of antisense Jabl or control plasmid (efficiency control, pEGFP cotransfection. Right, The antisense construct reduces Jabl in fibroblasts. c, Inhibition by MIF of Jabl-mediated reduction of serum dependence of fibroblasts. Proliferation of GFP-expressing cells is analysed in Jabl- and MIF- EFGP-overexpressing versus control vector-treated cells via BrdU incorporation. Data are means + SD of four determinations. d, MIF inhibits protea- some-mediated degradation of p27 Kιpl . Left, MIF reduces degradation of p27 Kιpl in pulse-chase labelled fibroblasts. [35S] p27 Kιpl levels shown from immuno- precipitations from rMIF- (+) versus buffer-treated cells. Right, MIF effect is proteasome-linked. As a, but incubations followed by treatment with DMSO, cycloheximide (CHX) , or LLnL. Figure 8 shows the mechanism of p27 Kipl induction by MIF. a, Effect of rMIF on p27 Kipl mRNA levels as analysed by Northern blotting. 1x10 7 NIH 3T3 fibroblasts were incubated in the presence or absence of rMIF (as indicated) for 40 h, cells washed in ice-cold PBS, and lysed in Trizol reagent (Gibco BRL, Life Technologies) . Total cellular RNA was isolated by the Trizol protocol, RNA quantitated, and applied to a standard Northern blotting procedure (Burger-Kentischer et al . , Kidney Int . 55, 1417-1425, 1999) . Probes were generated by the PCR- based DIG-labelling method (Roche Diagnostics) . The Kip probe corresponded to bases 8-181 of mouse Kipl (Genbank accession number U09968) and the human GAPDH probe was as described in Burger-Kentischer et al . . For transfections, cells were incubated with the plasmids pJabl and pClneo for 5 h and rested for 1 h before rMIF was added. Kip mRNA levels were found to be at comparable levels independent of whether fibroblasts were incubated with increasing concentrations of rMIF. Overexpression of Jabl following transient transfection of the pJabl vector also did not lead to a stimulatory effect of MIF on Kip RNA formation. A similar result was obtained when mRNA levels of Kip were analysed in Jurkat T cells (Kip/GAPDH ratios were: buffer, 1.0; 100 nM rMIF 0.8; 1 μM rMIF, 0.78). b, Effect of rMIF on p27 Kipl protein synthesis. 4x10 6 NIH 3T3 fibroblasts were synchronised by an overnight incubation in media containing 1% FCS, rMIF (1 μM) or control buffer were added, and cells incubated for another 36 h. Cells were washed in cyste- ine/methione-free media, incubated for 15 min in this media, and radioactivity (PROMIX, Amersham- Pharmacia Biotech) added. Cells were incubated for 60 min in the presence of the label, washed and Kip immunoprecipitated with anti-Kip antibody. Samples were electrophoresed in a 13% SDS-PAGE gel and radioactivity detected by a phoshoimager . c, Effect of recombinant MIF on formation of Kip/Jabl complexes in fibroblasts. NIH 3T3 fibroblasts were either incubated with LLnL for 4 h. Biotin-Jabl was overexpressed in TNT reticulocyte lysates. For control, TNT lysates were programmed with the pClneo control vector and aliquots from both lysates added to fibroblast lysates as indicated. Recombinant MIF (1 μM) or control buffer was added and the mixtures incubated for 2 h at coimmunoprecipitation conditions. Complexes were precipitated with anti-Kip antibody (Santa Cruz) . Immunoblots stained for either biotin-Jabl (upper panel) or Kipl (control, lower panel) were then performed to evaluate the potential effect of MIF on Kip/Jab complex formation. Example 7 : Mutant analysis and competition experiments. To investigate more closely those structural parts of MIF which are essential for Jabl binding and modulation, mutants were created. One mutant is mutant C60SMIF wherein in the wildtype MIF sequence the cysteine at position 60 has been replaced by a serine residue. Other mutants are MIF (50 - 65) which is a peptide fragment of wildtype MIF consisting of the 16 amino acid residues being present at position 50 - 65 of wildtype MIF. Mutant Ser Ser eo MIF (50 - 65) represents a mutant consisting of the wildtype amino acid residues at positions 50 - 65 of wildtype MIF wherein at position 57 a serine and in position 60 another serine has been inserted instead of the wildtype amino acids Cys at that position. The above given positions of amino acids are given in correlation with the published human MIF sequence described in Klee- man et al . , Figure 2 (1998 b) whose disclosure content is with respect to the amino acid sequence of MIF and its preparation wholly included in the disclosure of the present teaching. Mutant C60SMIF exhibits a clear structure activity profile. This mutant can be readily folded for use in activity assays but is devoid of the enzymatic oxidoreductase and immunological activity of MIF. It was found that C60SMIF, while capable of binding to biotin-Jabl, did not inhibit TNF-induced AP-1 activity, did not reduce Jabl-induced enhancement of c-Jun DNA binding, and exhibited reduced p27 Kιpl - inducing properties. Cys60 -spanning 16 residue MIF peptide, MIF (50 - 65) and Ser 57 Ser 60 MIF (50-65) strongly competed with wildtype MIF for Jabl binding, indicating together that this region is involved in the binding and modulation of Jabl. Figure 9 shows the characterisation of the binding site between MIF and Jabl. Sequence (50-65) of MIF but not the Cys60 residue alone is critical for interaction between MIF and Jabl. a, To investigate whether mutant C60SMIF also bound to Jabl, binding of rC60SMIF (r : recombinant) to biotin-labelled Jabl was compared with that of rwtMIF in vi tro in the TNT reticulocyte lysate. An anti-biotin S-HRP Western blot is shown (left panel) . Direct Western blotting analysis of rwtMIF and rC60SMIF verified that the anti-MIF antibody used for coimmunopre- cipitation exhibited comparable binding properties to both proteins (right panel) . b, MIF peptide (50- 65) , in a concentration-dependent manner, competes with wildtype MIF for binding of biotin-Jabl in vi tro in the TNT reticulocyte lysate system. An anti- biotin S-HRP Western blot is shown. An analogue of the MIF (50-65) peptide with the two Cys residues substituted for Ser was also tested and also competed for Jabl binding, confirming that the CALC Cys residues themselves (see a) are not critical for binding of Jabl. c, Mutant C60SMIF only showed reduced p27 Kipl -inducing properties as compared to wildtype MIF. Anti-Kipl Western blots from lysates of NIH 3T3 fibroblasts and Jurkat T cells incubated with rMIF or mutant C60SMIF (20 nM) are shown . Figure 10 shows the effect of MIF on growth arrest of fibroblasts. a, Effect of exogenously added rMIF on Jabl-mediated rescue of fibroblasts from starvation. NIH 3T3 fibroblasts were transfected with Jabl or control vector and cotransfected with EGFP. Cells were serum-starved for 2 h, rMIF added at the indicated concentrations, cells starved for another 36 h, incubated with BrdU for 18 h, and stained with anti-BrdU antibody. Only GFP-expressing cells were analysed. Data represent the mean ± SEM of 4 determinations (> 150 cells each) and are representative of 3 independent experiments. Exogenously added rMIF inhibited the Jabl effect in a dose- dependent manner. With 1.8 μM rMIF added a similar degree of inhibition was obtained as seen when EGFP-MIF was transfected (inhibition from ~ 80% to 40%; see manuscript) . b, Effect of rMIF on starvation-induced growth arrest of fibroblasts. Semi- confluent NIH 3T3 fibroblasts were synchronized by incubation in serum-free medium for 24 h. Culture medium was changed to medium with 0.5% FCS, containing either no further addition or rMIF at the indicated concentration. Incubation was continued in the presence of labelled thymidine for 16 h. Figure 10 is representative of two independent experiments and the data represent the mean ± SD of 6 measurements, c, Effect of anti-MIF antibody on cell growth of proliferating or serum-starved fibroblasts. Semi-confluent 3T3 cells were synchronized by incubation in serum-free medium for 24 h. Medium was changed to either serum-free (latter not shown) or 10% FCS-containing medium, containing either no further addition or 200 μg/ml of polyclonal anti-MIF antibody or 200 μg/ml unrelated rabbit IgG as control. Incubation was continued in the presence of labelled thymidine for 16 h. Figure 10 shows one of four experiments, using anti-MIF IgG in combination with 10 % FCS. Similar results were obtained when following synchronization, incubations were continued in serum-free media, d, Effect of endogenously overexpressed MIF on the growth of proliferating fibroblasts. NIH 3T3 fibroblasts were synchronized by incubation in media containing 0.5% serum for 18 h. Cells were switched to full-serum media conditions, transfected with Jabl or control vector and EGFP-MIF or EGFP, and incubated for another 40 h. The percentage of BrdU-positive cells was assessed as before. Data represent the mean ± SD of 4 determinations and are representative of 3 independent experiments . References 1. Bernhagen, J. Calandra, T., & Bucala, R. Regulation of the immune response by macrophage migration inhibitory factor: biological and structural features. J. Mol . Med. 76, 151-161 (1998) . 2. Bernhagen, J. et al . MIF is a pituitary- derived cytokine that potentiates lethal endo- toxaemia. Nature 365, 756-759 (1193) . 3. Calandra, T. et al . MIF as a glucocorticoid- induced modulator of cytokine production. Nature 377, 68-71 (1995) . 4. Donnelly, S.C. et al . Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nature Med. 3, 320-323 (1997) . 5. Kleeman, R. et al . Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as a thiol-protein oxidoreductase. J. Mol. Biol. 280, 85-102 (1998 a). 6. Kleeman, R. , Kapurniotu, A, Mischke, R. Held, J. & Bernhagen, J. Characterization of catalytic center mutants of macrophage migration inhibitory factor (MIF) and comparison with C81S MIF. Eur. J. Biochem. 261, 753-766 (1999) . 7. Rosengren, E. et al . The immunoregulatory mediator migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol. Med. 2, 143-149 (1996) . 8. Claret, F.-X Hibi, M. Dhut, S. Toda, T. & Karin, M. A new group of conserved coactiva- tors the increase the specificity of AP-1 transcription factors. Nature 383, 453-457 (1996) . 9. Tomoda, K. Kubota, Y. & Kato, J-Y. Degradation of the cyclin-dependent-kinase inhibitor p27 κ i P ι ig i ns tigated by Jabl. Nature 398, 160- 164 (1999) . 10. Bacher, M. et al . Migration inhibitory factor expression in experimentally induced endotoxemia. Am. J. Pathol. 15, 235-246 (1997). 11. Fields, S. & Song, 0. A novel genetic system to detect protein-protein interactions. Nature 340, 245-246 (1989) . 12. Bacher, M. et al . MIF expression in the rat brain - implications for neuronal function. Mol. Med. 4, 217-230 (1998) . 13. Ogata, A. Nishihira, J. Suzuki, T. Nagashima, K. & Tashiro, K. Identification of macrophage migration inhibitory factor mRNA expression in neural cells of the rat brain by in situ hybridization. Neurosci. Lett. 246, 173-177 (1998) . 14. Bernhagen, J. et al . Purification, bioactiv- ity, and secondary structure analysis of mouse and human macrophage migration inhibitory factor (MIF) . Biochemistry 33, 14144-14155 (1994) . 15. Sun, H., Bernhagen, J. , Bucala, R. & Lolis, E. Crystal structure at 2.6 A resolution of human macrophage migration inhibitory factor. Proc. Natl. Acad. Sci. USA 93, 5191-5196 (1996). 16. Seeger, M. et al . A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits. FASEB J. 12, 469-478 (1998) . 17. Hofmann, K. & Bucher P. The PCI domain: a common theme in three multiprotein complexes. Trends Biochem. Sci. 23, 204-205 (1998). 18. Asano, K. et al . Structure of cDNAs encoding human eukaryotic initiation factor 3 subunits. J. Biol. Chem. 272, 27042-27052 (1997). 19. Karin, M. The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 270, 16483-16486 (1995). 20. Hirota, K. et al . AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc. Natl. Acad. Sci. USA 94, 3633-3638 (1997). 21. Wilhelm, D., Bender, K. , Knebel, A. & Angel, P. The level of intracellular glutathione is a kex factor for the induction of stress- activated signal transduction pathways including Jun N-terminal protein kinases and p38 kinase by alkylating agents. Mol. Cell. Biol. 17, 4792-4800 (1997) . 22. Lanathan, A., Williams, J.B., Sanders, L.K. & Nathans, D. Growth factor-induced delayed early response genes. Mol. Cell. Biol. 12, 3919-3929 (1992) . 23. Wistow, G.J., Shaughnessy, M.P., Lee, D.C., Hodin, J. & Zelenka, P.S. A macrophage migration inhibitory factor is expressed in the differentiating cells of the eye lens. Proc. Natl. Acad. Sci. USA 90, 1271-1280 (1993). 24. Scheinman, R.I., Cogswell, P.C., Lofquist, A. K. & Baldwin, A.S.;. Role of transcriptional activation of IκBα in mediation of immunosup- pression by glucocorticoids . Science 270, 283- 289 (1995) . 25. Mitchell, R.A. Metz, CN. , Peng, T. & Bucala, R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 acti- vaion by macrophage migration inhibitory factor (MIF) . Regulatory role in cell proliferation and glucocorticoid action. J. Biol. Chem. 274, 18100-18106 (1999) . 26. Dedio, J., Jahnen-Dechent , W. , Bachmann, M. & Muller-Esterl, W. The multiligand-binding protein gClqR, putative Clq receptor, is a mito- chondrial protein. J. Immunol. 160, 3534-3542 (1998) . 27. Johannes, F.J. et al . Protein kinase Cμ down- regulation of tumor-necrosis-factor-induced apoptosis correlates with enhanced expression of nuclear-factor-kappaB-dependent protective genes. Eur.J. Biochem. 257, 47-54 (1998). 28. Angel, P. et al . Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated transactivating factor. Cell 49, 729-736 (1987) . 29. Berberich, I. et al . Cross-linking CD40 on B cells preferentially induces stress-activated protein kinases rather than mitogen-activated protein kinases. EMBO J. 15, 92-101 (1996). 30. Roger et al . Increased AP-1 and NFKB activity and increased stability of IL-8 mRNA are implicated in superinduction of IL-8 mRNA by H292 cells. Biochem. J. 330, 429-435 (1998) 31. Waeber et al . Insulin secretion is regulated by the glucose dependent production of islet beta cell MIF. Proc. Natl. Acad. Sci. USA 94, 4782-4-787 (1997) 32. Kleemann et al . Specific reduction of insulin disulfides by macrophage migration inhibitory factor (MIF) with glutathione and dihydrol- ipoamide : potential role in cellular redox processes. FEBS Lett. 430, 191-196 (1998 b) .

Claims: Claims 1. A method for screening candidate drugs by testing whether the candidate drug disrupts an interaction between MIF (macrophage migration inhibitory factor) and Jabl (c-Jun activation domain binding protein) and/or whether the candidate drug interferes specifically with MIF- Jabl-dependent action, the method comprising detecting in a MIF and Jabl system in the absence of the candidate drug an interaction between MIF and Jabl and/or a MIF-Jabl-dependent action and comparing the detected interaction and/or action to an interaction and/or action detected in the MIF and Jabl system in the presence of the candidate drug. 2. The method of claim 1, wherein the method is an in vitro method. 3. The method of claim 2, wherein the MIF and Jabl interaction is detected by a binding assay. 4. The method of claims 1 to 3 , wherein the binding is measured by using radioactive or photo- labelled MIF, Jabl, MIF-Jabl-complex and/or antibodies thereof. 5. The method of claims 1 to 4 , wherein the binding is measured by using an electromobility shift assay. 6. The method of claims 1 to 5, wherein non- immobilised MIF, Jabl, a MIF-Jabl-complex and/or antibodies thereof bind to immobilised MIF, Jabl, MIF-Jabl-complex and/or antibodies thereof and a resulting complex is separated by sedimentation, in particular by centrifugation or filtration. 7. The method of claims 1 to 6, wherein the binding is measured by chromatographic fractiona- tion. 8. The method of claims 1 to 7, wherein MIF and Jabl are obtained by in vitro translation. 9. The method of claims 1 to 8 , wherein MIF and Jabl are contained in a crude cell extract. 10. The method of claims 1 to 9, wherein the method is an in vivo method. 11. The method of claims 1 to 10 comprising a) providing a cell overexpressing MIF and/or Jabl, b) detecting expression of a MIF-Jabl- complex target activity, in particular of a reporter gene in the absence of the candidate drug, c) detecting expression of the MIF-Jabl- complex target activity, in particular of a reporter gene in the presence of the candidate drug and d) comparing the results obtained in b) and c) . 12. The method of claims 1 to 11, wherein the cell overexpressing MIF and/or Jabl comprises a reporter gene capable of being induced by a MIF- Jabl-complex. 13. The method of claims 1 to 12, wherein the cell overexpressing MIF and/or Jabl is obtained by transfecting a host cell with a) a vector comprising a MIF coding sequence under the operational control of a promoter, a vector comprising a Jabl coding sequence under the operational control of a promoter and a vector comprising a reporter gene or b) a vector containing the MIF and Jabl coding gene under the operational control of a single promoter and a vector comprising a reporter gene or c) a vector containing the MIF and Jabl coding sequence and a reporter gene under the operational control of a single promoter. 14. The method of claims 1 to 13, comprising: a) providing a cell containing: i) a reporter gene, operably linked to a DNA-binding protein recognition site; ii) a first fusion gene expressing a first hybrid protein comprising MIF covalently bonded to a DNA-binding moiety which specifically binds to a DNA-binding protein recognition site; and iii) a second fusion gene expressing a second hybrid protein comprising Jabl covalently bonded to a gene activating moiety, wherein Jabl binds MIF in the absence of the candidate drug; b) contacting the cell with the candidate drug under conditions allowing expression of the reporter gene; and c) detecting inhibition of expression of the reporter gene as a measure of the ability of the candidate drug to disrupt binding between MIF and Jabl. 15. A method for detecting an interaction between MIF and Jabl, the method comprising: a) providing a cell containing a reporter gene wherein the reporter gene expresses a reporter protein when the reporter gene is activated by an amino acid sequence, including a transcriptional activation domain when the transcriptional activation domain is in sufficient proximity to the reporter gene, b) providing a first chimeric gene that is capable of being expressed in host cells, the first chimeric gene comprising a DNA sequence that encodes a first hybrid protein, the first hybrid protein comprising: i) a DNA-binding domain that recognises a binding site of the reporter gene in the cell; and ii) the MIF protein or a part thereof, c) providing a second chimeric gene that is capable of being expressed in the host cell, the second chimeric gene comprising a DNA sequence that encodes a second hybrid protein, the second hybrid protein comprising: i) the transcriptional activation domain, and ii) the Jabl protein or a part thereof, iii) wherein interaction between the MIF protein and the Jabl in the cell causes the transcriptional activation domain to activate transcription of the reporter gene, d) introducing the first chimeric gene and the second chimeric gene into the cell, e) subjecting the cell to conditions under which the first hybrid protein and the second hybrid protein are expressed in sufficient quantity for the reporter gene to be activated, and f) determining whether the reporter gene has been expressed to a degree greater than expression in the absence of the interaction between the MIF protein and the Jabl protein. 16. The method of claim 15, wherein the expression of the reporter gene is determined in cells subjected to a candidate drug to be screened and compared to the expression of the reporter gene in cells not subjected to the drug. 17. The method of claims 15 or 16, wherein the DNA-binding domain and transcriptional activation domain are derived from transcriptional activators having separable DNA-binding and transcriptional activations domain. 18. The method of claims 15 to 17, wherein the DNA-binding domain in the transcriptional activation domain is selected from the group consisting of transcriptional activators GAL4, GCN4 and ADR1. 19. The method of claims 15 to 18, wherein the first hybrid protein and/or the second hybrid protein is encoded on a library of plasmids containing DNA inserts, derived from the group consisting of genomic DNA, cDNA and synthetically generated DNA. 20. The method of claims 15 to 19, wherein the chimeric genes are introduced into the cell in the form of plasmids . 21. The method of claims 15 to 20, wherein the first chimeric gene is integrated into a chromosome of the cell. 22. The method of claims 15 to 21, wherein the first chimeric gene is integrated into a chromosome of the cell and the second chimeric gene is introduced into the host cell as a part of a plasmid. 23. The method of claims 15 to 22, wherein the DNA-binding domain and the transcriptional activation domain are from different transcriptional activators. 24. The method according to any one of claims 1 to 23, wherein the interaction between MIF and Jabl is tested in the presence of a MIF or Jabl competitive peptide . 25. The method according to claim 24, wherein the MIF competitive peptide is MIF (50 - 65) (SEQ ID No. 1) or Ser 57 Ser 60 MIF (50 - 65) (SEQ ID No. 2) . 26. A method of preparing MIF comprising a) providing a first source containing MIF, b) contacting the first source containing MIF with a second source containing Jabl under conditions allowing for the binding of MIF and Jabl and c) separating MIF from Jabl. 27. A method of preparing Jabl comprising a) providing a first source containing Jabl, b) contacting the first source containing Jabl protein with a second source containing MIF under conditions allowing for the binding of MIF and Jabl and c) separating Jabl from MIF. 28. The method of claims 26 or 27, wherein the source is a cell, tissue, cell culture, cell culture supernatant, cell extract, protein preparation, isolated MIF or Jabl. 29. The method according to claim 26 to 28, wherein the sources are digested prior to contacting the sources. 30. A protein complex comprising all or a part of MIF in association with all or a part of Jabl, optionally in association with p27Kipl and/or c-Jun and/or c-Jun-amino-terminal kinase and/or steroid receptor coactivator 1 and/or integrin LFA-1 and/or progesterone receptor and/or glucocorticoide receptor. 31. A fusion protein comprising all or a part of MIF in conjunction with all or part of Jabl, optionally in conjunction with p27Kipl and/or c-Jun and/or c-Jun-amino-terminal kinase and/or steroid receptor coactivator 1 and/or integrin LFA-1 and/or progesterone receptor and/or glucocorticoide receptor. 32. A nucleic acid sequence encoding the complex protein or the fusion protein of claim 30 or 31 or the complementary strand thereof. 33. A vector comprising the nucleic acid sequence of claim 32. 34. A host cell comprising the vector of claim 33. 35. An antibody or fragment thereof recognising specifically the complex and/or the fusion protein of claim 30 and/or claim 31. 36. The antibody according to claim 35, wherein the antibody is a monoclonal antibody. 37. The antibody according to claim 35, wherein the antibody is a polyclonal antibody. 38. The antibody of claims 35 to 37 wherein the antibody is a humanized antibody. 39. The antibody of claims 35 to 38, wherein the antibody is a human antibody. 40. The antibody of claims 35 to 39, wherein the antibody or a fragment thereof has a detectable label and/or the antibody or a fragment thereof is modified. 41. A kit comprising the complex protein of claim 30, the fusion protein of claim 31, the nucleic acid sequences of claim 32, the vector of claim 33, the host cell of claim 34, the DNA sequence encoding Jabl , the DNA sequence encoding MIF and/or the antibodies according to claims 35 to 40. 42. A pharmaceutical or diagnostic composition comprising the complex protein of claim 30, the fusion protein of claim 31, the nucleic acid sequence of claim 32, the vector of claim 33, the host cell of claim 34, the DNA sequence encoding Jabl, the DNA sequence encoding MIF and/or the antibodies according to claims 35 to 40, optionally in conjunction with a pharmaceutically acceptable carrier. 43. Use of the Jabl or a Jabl coding nucleotide sequence to modulate the activity of MIF, in particular for treatment of MIF-related diseases . 44. Use of Jabl or the Jabl coding nucleotide sequence for preparing a drug for the diagnosis and/or treatment of MIF-related diseases. 45. Use of Jabl or the Jabl coding nucleotide sequence for the diagnosis and/or treatment of MIF-related diseases. 46. Use of the complex protein of claim 30 and/or the fusion protein of claim 31 for preparing a drug for the diagnosis and/or treatment of MIF-related diseases. 47. Use of the complex protein of claim 30 and/or the fusion protein of claim 31 for the diagnosis and/or treatment of MIF-related diseases. 48. Use of the antibody of claims 35 to 40 or an antibody to Jabl or a fragment thereof for preparing a drug for the diagnosis and/or treatment of MIF-related diseases. 49. Use of the antibody of claims 35 to 40 or an antibody to Jabl or a fragment thereof for the diagnosis and/or treatment of MIF-related diseases . 50. A drug comprising Jabl or a part thereof or a Jabl coding nucleotide sequence or an antibody specifically recognising Jabl in a pharmaceutically effective amount, optionally in conjunction with a pharmaceutically acceptable carrier. 51. Use of the MIF or an MIF coding nucleotide sequence to modulate the activity of Jabl, in particular for treatment of MIF-related diseases . 52. Use of MIF or the MIF coding nucleotide sequence for preparing a drug for the diagnosis and/or treatment of Jabl-related diseases. 53. Use of MIF or the MIF coding nucleotide sequence for the diagnosis and/or treatment of Jabl-related diseases. 54. Use of the complex protein of claim 30 and/or the fusion protein of claim 31 for preparing a drug for the diagnosis and/or treatment of Jabl-related diseases. 55. Use of the complex protein of claim 30 and/or the fusion of claim 31 for the diagnosis and/or treatment of Jabl-related diseases. 56. Use of the antibody of claims 35 to 40 or antibody to MIF or a fragment thereof for preparing a drug for the diagnosis and treatment of Jabl-related diseases. 57. Use of the antibody of claims 35 to 40 or an antibody to MIF or a fragment thereof for the diagnosis and/or treatment of Jabl-related diseases . 58. A drug comprising MIF or a part thereof or a MIF coding nucleotide sequence or an antibody specifically recognising MIF in a pharmaceutically effective amount, optionally in conjunction with a pharmaceutically acceptable carrier. 59. A non-human mammalian cell exhibiting a modified MIF and Jabl expression. 60. The cell according to claim 59 containing at least one mutation in each of its MIF and Jabl genes . 61. The cell according to claim 59, which contains MIF and/or Jabl antisense constructs interfering with the expression of the endogenous MIF and Jabl genes. 62. A non-human mammal containing a cell according to any one of claims 59 to 61. 63. A human cell exhibiting a modified MIF and Jabl expression. 64. The cell according to claim 63 containing at least one mutation in each of its MIF and Jabl genes . 65. The cell according to claim 63, which contains MIF and/or Jabl antisense constructs interfering with the expression of the endogenous MIF and Jabl genes . 66. A non-human mammal containing a cell according to any one of claims 63 to 65. 67. Use of a cell according to any of claims 59 to 61 or 63 to 65 for gene therapy purposes.

Inventors: BERNHAGEN JUERGEN, BRUNNER HERWIG, KAPURNIOTU AFRODITI, KLEEMANN ROBERT, MISCHKE RALF, BERNHAGEN, JUERGEN, BRUNNER, HERWIG, KAPURNIOTU, AFRODITI, KLEEMANN, ROBERT, MISCHKE, RALF
Applicants: BERNHAGEN JUERGEN, BRUNNER HERWIG, FRAUNHOFER GES FORSCHUNG, KAPURNIOTU AFRODITI, KLEEMANN ROBERT, MISCHKE RALF, BERNHAGEN, JUERGEN, BRUNNER, HERWIG, FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V., KAPURNIOTU, AFRODITI, KLEEMANN, ROBERT, MISCHKE, RALF
Application year: 2000
Main classification: C12Q1
IPC codes: A61K31, A61K35, A61K38, A61K39, A61K48, A61P3, A61P11, A61P13, A61P17, A61P19, A61P25, A61P27, A61P29, A61P31, A61P35, A61P37, A61P43, C07K14, C07K16, C07K19, C12N1, C12N5, C12N15, C12P21, C12Q1, G01N33